Influenza Vaccines: Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.Influenza, Human: An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.Influenza A virus: The type species of the genus INFLUENZAVIRUS A that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces.Influenza A Virus, H1N1 Subtype: A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Influenza B virus: Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.Influenza A Virus, H3N2 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.Influenza in Birds: Infection of domestic and wild fowl and other BIRDS with INFLUENZA A VIRUS. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic POULTRY.Influenza A Virus, H5N1 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 1. The H5N1 subtype, frequently referred to as the bird flu virus, is endemic in wild birds and very contagious among both domestic (POULTRY) and wild birds. It does not usually infect humans, but some cases have been reported.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Hemagglutination Inhibition Tests: Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.Hemagglutinin Glycoproteins, Influenza Virus: Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.Orthomyxoviridae Infections: Virus diseases caused by the ORTHOMYXOVIRIDAE.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Orthomyxoviridae: A family of RNA viruses causing INFLUENZA and other diseases. There are five recognized genera: INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; ISAVIRUS; and THOGOTOVIRUS.Pandemics: Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Polysorbates: Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Vaccines, Combined: Two or more vaccines in a single dosage form.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.SqualeneVaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Attenuated: Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.Cross Protection: Protection conferred on a host by inoculation with one strain or component of a microorganism that prevents infection when later challenged with a similar strain. Most commonly the microorganism is a virus.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Seasons: Divisions of the year according to some regularly recurrent phenomena usually astronomical or climatic. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Influenza A Virus, H9N2 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 9 and neuraminidase 2. The H9N2 subtype usually infects domestic birds (POULTRY) but there have been some human infections reported.Influenza A Virus, H2N2 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 2 and neuraminidase 2. The H2N2 subtype was responsible for the Asian flu pandemic of 1957.Influenza A Virus, H3N8 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 8. The H3N8 subtype has frequently been found in horses.Administration, Intranasal: Delivery of medications through the nasal mucosa.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Vaccines, Virosome: Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.Disease Outbreaks: Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.Neuraminidase: An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992)Immunization Schedule: Schedule giving optimum times usually for primary and/or secondary immunization.Injections, Intradermal: The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Hemagglutinins, Viral: Specific hemagglutinin subtypes encoded by VIRUSES.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Immunization Programs: Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Reassortant Viruses: Viruses containing two or more pieces of nucleic acid (segmented genome) from different parents. Such viruses are produced in cells coinfected with different strains of a given virus.Technology Transfer: Spread and adoption of inventions and techniques from one geographic area to another, from one discipline to another, or from one sector of the economy to another. For example, improvements in medical equipment may be transferred from industrial countries to developing countries, advances arising from aerospace engineering may be applied to equipment for persons with disabilities, and innovations in science arising from government research are made available to private enterprise.Antibodies, Neutralizing: Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Technology, Pharmaceutical: The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients.Mass Vaccination: Administration of a vaccine to large populations in order to elicit IMMUNITY.Immunity, Humoral: Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.Influenza A Virus, H7N9 Subtype: A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Mice, Inbred BALB CPapillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.Sentinel Surveillance: Monitoring of rate of occurrence of specific conditions to assess the stability or change in health levels of a population. It is also the study of disease rates in a specific cohort such as in a geographic area or population subgroup to estimate trends in a larger population. (From Last, Dictionary of Epidemiology, 2d ed)Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.Ferrets: Semidomesticated variety of European polecat much used for hunting RODENTS and/or RABBITS and as a laboratory animal. It is in the subfamily Mustelinae, family MUSTELIDAE.Meningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.Influenza A Virus, H7N7 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 7 and neuraminidase 7. The H7N7 subtype produced an epidemic in 2003 which was highly pathogenic among domestic birds (POULTRY). Some infections in humans were reported.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Birds: Warm-blooded VERTEBRATES possessing FEATHERS and belonging to the class Aves.Hemagglutinins: Agents that cause agglutination of red blood cells. They include antibodies, blood group antigens, lectins, autoimmune factors, bacterial, viral, or parasitic blood agglutinins, etc.Madin Darby Canine Kidney Cells: An epithelial cell line derived from a kidney of a normal adult female dog.Influenzavirus B: A genus of the family ORTHOMYXOVIRUS causing HUMAN INFLUENZA and other diseases primarily in humans. In contrast to INFLUENZAVIRUS A, no distinct antigenic subtypes of hemagglutinin (HEMAGGLUTININS) and NEURAMINIDASE are recognized.United StatesInfluenza A Virus, H5N2 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 2. The H5N2 subtype has been found to be highly pathogenic in chickens.Hepatitis B Vaccines: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.Neutralization Tests: The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).Measles Vaccine: A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)Vaccines, Virus-Like Particle: Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.Virus Shedding: The expelling of virus particles from the body. Important routes include the respiratory tract, genital tract, and intestinal tract. Virus shedding is an important means of vertical transmission (INFECTIOUS DISEASE TRANSMISSION, VERTICAL).Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)Haemophilus Vaccines: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.Rabies Vaccines: Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.Antiviral Agents: Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.Influenzavirus A: A genus in the family ORTHOMYXOVIRIDAE causing influenza and other diseases in humans and animals. It contains many strains as well as antigenic subtypes of the integral membrane proteins hemagglutinin (HEMAGGLUTININS) and NEURAMINIDASE. The type species is INFLUENZA A VIRUS.Rotavirus Vaccines: Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.Cholera Vaccines: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.Population Surveillance: Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy.Vaccine Potency: The relationship between an elicited ADAPTIVE IMMUNE RESPONSE and the dose of the vaccine administered.Viral Matrix Proteins: Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)Typhoid-Paratyphoid Vaccines: Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.Product Surveillance, Postmarketing: Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.Smallpox Vaccine: A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)Alum Compounds: Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.Tuberculosis Vaccines: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.Influenza A Virus, H1N2 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 1 and neuraminidase 2. It is endemic in both human and pig populations.Chickenpox Vaccine: A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.Diphtheria-Tetanus-Pertussis Vaccine: A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.Immunity, Cellular: Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.Mumps Vaccine: Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.Virus Replication: The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.Hepatitis A Vaccines: Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Hospitalization: The confinement of a patient in a hospital.Enzyme-Linked Immunospot Assay: A method of detection of the number of cells in a sample secreting a specific molecule. With this method, a population of cells are plated over top of the immunosorbent substrate that captures the secreted molecules.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Measles-Mumps-Rubella Vaccine: A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.Centers for Disease Control and Prevention (U.S.): An agency of the UNITED STATES PUBLIC HEALTH SERVICE that conducts and supports programs for the prevention and control of disease and provides consultation and assistance to health departments and other countries.Viral Proteins: Proteins found in any species of virus.Lung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Amantadine: An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.Chickens: Common name for the species Gallus gallus, the domestic fowl, in the family Phasianidae, order GALLIFORMES. It is descended from the red jungle fowl of SOUTHEAST ASIA.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Streptococcal Vaccines: Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Anthrax Vaccines: Vaccines or candidate vaccines used to prevent ANTHRAX.DucksDengue Vaccines: Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.Aluminum Hydroxide: A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.Virus Cultivation: Process of growing viruses in live animals, plants, or cultured cells.Reverse Genetics: The use of techniques that produce a functional MUTATION or an effect on GENE EXPRESSION of a specific gene of interest in order to identify the role or activity of the gene product of that gene.Poultry: Domesticated birds raised for food. It typically includes CHICKENS; TURKEYS, DUCKS; GEESE; and others.Dose-Response Relationship, Immunologic: A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.United States Dept. of Health and Human Services: A cabinet department in the Executive Branch of the United States Government concerned with administering those agencies and offices having programs pertaining to health and human services.Immunity, Mucosal: Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.Placebos: Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.Viral Hepatitis Vaccines: Any vaccine raised against any virus or viral derivative that causes hepatitis.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Immunity: Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Needles: Sharp instruments used for puncturing or suturing.Tetanus ToxoidAntibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Poliovirus Vaccine, Oral: A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)RNA, Viral: Ribonucleic acid that makes up the genetic material of viruses.Nucleoproteins: Proteins conjugated with nucleic acids.Yellow Fever Vaccine: Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.Hemagglutination, Viral: Agglutination of ERYTHROCYTES by a virus.Health Personnel: Men and women working in the provision of health services, whether as individual practitioners or employees of health institutions and programs, whether or not professionally trained, and whether or not subject to public regulation. (From A Discursive Dictionary of Health Care, 1976)Plague Vaccine: A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.Nasopharynx: The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function.Fungal Vaccines: Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.Nose: A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.Infant, Newborn: An infant during the first month after birth.Influenzavirus C: A genus of the family ORTHOMYXOVIRIDAE comprising viruses similar to types A and B but less common, more stable, more homogeneous, and lacking the neuraminidase protein. They have not been associated with epidemics but may cause mild influenza. Influenza C virus is the type species.Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.World Health: The concept pertaining to the health status of inhabitants of the world.Influenza A Virus, H7N3 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 7 and neuraminidase 3. It was first detected in turkeys in Britain in 1963 and there have been several outbreaks on poultry farms since that time. A couple cases of human infections have been reported.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.World Health Organization: A specialized agency of the United Nations designed as a coordinating authority on international health work; its aim is to promote the attainment of the highest possible level of health by all peoples.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Cloaca: A dilated cavity extended caudally from the hindgut. In adult birds, reptiles, amphibians, and many fishes but few mammals, cloaca is a common chamber into which the digestive, urinary and reproductive tracts discharge their contents. In most mammals, cloaca gives rise to LARGE INTESTINE; URINARY BLADDER; and GENITALIA.Rubella Vaccine: A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Vaccines, Acellular: Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Hemagglutination Tests: Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)Egg Hypersensitivity: Allergic reaction to eggs that is triggered by the immune system.Immunologic Memory: The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.Patient Acceptance of Health Care: The seeking and acceptance by patients of health service.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.Pneumococcal Vaccines: Vaccines or candidate vaccines used to prevent infections with STREPTOCOCCUS PNEUMONIAE.SAIDS Vaccines: Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.Nasal Mucosa: The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells.Salmonella Vaccines: Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.Phylogeny: The relationships of groups of organisms as reflected by their genetic makeup.Ebola Vaccines: Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.Chick Embryo: The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Hong Kong: The former British crown colony located off the southeast coast of China, comprised of Hong Kong Island, Kowloon Peninsula, and New Territories. The three sites were ceded to the British by the Chinese respectively in 1841, 1860, and 1898. Hong Kong reverted to China in July 1997. The name represents the Cantonese pronunciation of the Chinese xianggang, fragrant port, from xiang, perfume and gang, port or harbor, with reference to its currents sweetened by fresh water from a river west of it.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Administration, Mucosal: Delivery of a drug or other substance into the body through the epithelium lining of MUCOUS MEMBRANE involved with absorption and secretion.Hemadsorption Inhibition Tests: Serological tests that measure anti-hemadsorption agents such as antiviral ANTIBODIES that block VIRAL HEMAGGLUNININS from adhering to the surface of red blood cells.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Drug Storage: The process of keeping pharmaceutical products in an appropriate location.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Spain: Parliamentary democracy located between France on the northeast and Portugual on the west and bordered by the Atlantic Ocean and the Mediterranean Sea.Mice, Inbred C57BLViral Core Proteins: Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID.Diphtheria-Tetanus-acellular Pertussis Vaccines: Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.RNA Replicase: An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293)Communicable Disease Control: Programs of surveillance designed to prevent the transmission of disease by any means from person to person or from animal to man.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Staphylococcal VaccinesSwine: Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Viral Nonstructural Proteins: Proteins encoded by a VIRAL GENOME that are produced in the organisms they infect, but not packaged into the VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY.Vero Cells: A CELL LINE derived from the kidney of the African green (vervet) monkey, (CERCOPITHECUS AETHIOPS) used primarily in virus replication studies and plaque assays.Cytomegalovirus Vaccines: Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.Licensure: The legal authority or formal permission from authorities to carry on certain activities which by law or regulation require such permission. It may be applied to licensure of institutions as well as individuals.Human Experimentation: The use of humans as investigational subjects.Anseriformes: An order of BIRDS comprising the waterfowl, particularly DUCKS; GEESE; swans; and screamers.Emulsions: Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.GeorgiaEpitopes, T-Lymphocyte: Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.

*  IVW - Influenza Vaccines for the World Conference - Bvents.Com
Influenza Vaccines for the World Conference April 2017 such as venue, list of exhibitors, keynote ... Manufacturing Issues Vaccine Usage / Targeting Strategies Influenza Vaccines / Adjuvants - ... IVW - Influenza Vaccines for the World Conference 2017. conferences > Health conferences > IVW - ... Improvement Issues Universal influenza vaccines developments Pandemic Preparedness Issues / ......
http://bvents.com/event/471426-ivw-influenza-vaccines-for-the-world-conference
*  Vaccines for preventing seasonal influenza and its complications in people aged...
Vaccines for preventing flu in people with asthma. *Vaccines for preventing influenza in healthy ... Trivalent inactivated vaccines are the most commonly used influenza vaccines. Due to the poor ... To assess the effectiveness of vaccines in preventing influenza, influenza-like illness (ILI), ... or effectiveness against influenza-like illness (ILI) or safety. Any influenza vaccine given ......
http://cochrane.org/CD004876/ARI_vaccines-for-preventing-seasonal-influenza-and-its-complications-in-people-aged-65-or-older
*  Influenza vaccines, KOPS, and the truth.
money adverse reactions influenza hypocrisy medical system Dr Offit Influenza vaccine brainwashing ... Influenza vaccines, KOPS, and the truth. Hilary Butler - Wednesday, June 01, 2011 ... It isn't "just" influenza that is counted in the stats. It's "influenza-like illnesses". The two, ... which gave a very low efficacy to their influenza vaccine, had a similar interesting situation:. ......
http://beyondconformity.co.nz/hilarys-desk/influenza_vaccines_kops_and_the_truth
*  Influenza cases increasing throughout Montana - Public health officials...
Influenza-related hospitalizations across the state have also increased. As of January 4, 2014 ... DPHHS influenza surveillance for the 2013-14 season officially began on October 1, 2013. ... Further, one death from complications of influenza was reported last week in a Hill County resident ... Influenza activity is widespread in Montana with half of the counties reporting confirmed cases, ......
http://states.aarp.org/influenza-cases-increasing-throughout-montana-public-health-officials-encourage-influenza-vaccine/
*  Analysis finds Ontario's universal flu vaccination policy cost-effective |...
... which targets free flu vaccine for anyone over 6 months old, is cost-effective and may be an ... Ebola Vaccine Team B. *Influenza Training. *News Publishing. *Public Health Practices. *About Us* ... They found that Ontario's universal flu vaccine program cost about twice as much as the targeted ... Most Canadian provinces target free seasonal flu vaccines to people age 65 and older, those with ......
http://cidrap.umn.edu/news-perspective/2010/04/analysis-finds-ontarios-universal-flu-vaccination-policy-cost-effective
*  March/April 2014 - Volume 20 - Issue 2 : Journal of Public Health Management...
Differences in Adult Influenza Vaccine-Seeking Behavior: The Roles of Race and Attitudes. Groom, ... study was to determine whether there are differences between blacks and whites in influenza vaccine ......
http://journals.lww.com/jphmp/toc/2014/03000
*  Search Index
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was ......
http://globenewswire.com/Search?tag= Inc.
*  HKU Scholars Hub: Swine-origin influenza virus like particle vaccine conferred...
Clinical Panenza vaccine. -. dc.title. Swine-origin influenza virus like particle vaccine conferred ... vaccine against influenza virus infection and compare the efficiency of this vaccine with the ... vaccine against influenza virus infection and compare the efficiency of this vaccine with the ... Swine-origin influenza virus like particle vaccine conferred complete protection against lethal ......
http://hub.hku.hk/handle/10722/135937
*  What are Pneumonia Symptoms in Children? (with Pictures) | eHow
Get a flu vaccine yearly, since influenza can lead to pneumonia. • Practice healthy habits at home ... including influenza virus, adenovirus, parainfluenza virus and respiratory synctial virus (RSV is ... Get a preventative shot known as the pneumococcal conjugate vaccine. • ......
http://ehow.com/about_5098692_pneumonia-symptoms-children.html
*  Oswego, IL - Belgian Malinois/German Shepherd Dog Mix. Meet Radar a Dog for...
Rabies vaccine. • Bordatella vaccine for dogs. • Canine Influenza vaccine for dogs. • Booster for ... leukemia test/vaccine if adopting a cat)). We can call your veterinarian to get this information, ... Vaccines current to the date of adoption *:. • ......
http://adoptapet.com/pet/18799216-oswego-illinois-belgian-malinois-mix
*  "PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis"
PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis. PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis - New Market Report Fast Market Research recommends PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis from GlobalData, now available. Boston, MA -- SBWIRE -- 02/16/2013 -- GlobalData has released its new Country report, "PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis". GlobalData does not project that intradermal and intranasal vaccines will enter the Japan market during the forecast period, leaving all market dynamics between existing and new intramuscular vaccines. - Sales forecast for the top drugs in Japan from 2012 to 2022. - Analysis of the impact of key events as well the drivers and restraints affecting the Japan seasonal influenza market. - PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis - PharmaPoint: Seasonal Influenza Vaccines France...
http://sbwire.com/press-releases/pharmapoint-seasonal-influenza-vaccines-japan-drug-forecast-and-market-analysis-new-market-report-206774.htm
*  Assessing the Evidence: Live Attenuated Influenza Vaccine in... : The Pediatric Infectious Diseas
Assessing the Evidence: Live Attenuated Influenza Vaccine in... Assessing the Evidence: Live Attenuated Influenza Vaccine in... Assessing the Evidence: Live Attenuated Influenza Vaccine in Children Younger than 2 Years. We included studies enrolling healthy children 2 years of age who received LAIV, compared with placebo or inactivated influenza vaccine IIV. LAIV vaccines have been shown to have higher immunogenicity in children 1–5 years of age 13 and higher efficacy in children 2 years of age, 14 when compared with IIV. Back to Top. Back to Top. Article Outline Eligibility Criteria Following a predesigned protocol, we included RCTs that enrolled healthy children 2 years of age who received LAIV and evaluated its effectiveness and safety, compared with placebo or IIV only seasonal vaccines. Back to Top. Meta-analysis of these studies showed an increased risk for the development of rhinorrhea in children who received LAIV compared with placebo RR = 1.18, 95% CI: 1.07–1.31, P 0.05, I 2 = 28.3%. Article Outline...
http://journals.lww.com/pidj/Fulltext/2014/04000/Assessing_the_Evidence__Live_Attenuated_Influenza.20.aspx?WT.mc_id=HPxADx20100319xMP
*  Interim Results: State-Specific Seasonal Influenza Vaccination Coverage --- United States, August 20
... 09--January 2010. Skip directly to search Skip directly to A to Z list Skip directly to site content. CDC Home CDC 24/7: Saving Lives. Protecting People. Search The CDC. Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov. Morbidity and Mortality Weekly Report MMWR. MMWR. Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation in the subject line of e-mail. Interim Results: State-Specific Seasonal Influenza Vaccination Coverage --- United States, August 2009--January 2010 Please note: An erratum has been published for this article. To view the erratum, please click here. The advent of the 2009 influenza A H1N1 pandemic in April 2009 made the 2009--10 influenza season highly unusual. Public awareness of the potential seriousness of influenz...
http://cdc.gov/mmwr/preview/mmwrhtml/mm5916a1.htm?s_cid=mm5916a1_e
*  WHO | QUESTIONS AND ANSWERS ON PANDEMIC INFLUENZA VACCINE
Countries. Immunization, Vaccines and Biologicals. Development of pandemic influenza vaccine What is the difference between seasonal influenza vaccines, "pre-pandemic" vaccines, and pandemic vaccines. Seasonal influenza vaccines refer to vaccines that are updated yearly and that protect against currently circulating influenza viruses. It will protect against the pandemic influenza strain but will only be available after the emerging virus of the next influenza pandemic has been isolated. Where do we stand in terms of developing an effective pandemic influenza vaccine. Several streams of development are promising: among them, inactivated split the technology currently used for seasonal influenza vaccines vaccines with an adjuvant, whole virus vaccines and live attenuated vaccines. Will a vaccine be a magic bullet to control an influenza pandemic. How long will it take to produce the first doses of pandemic influenza vaccine in the event of a pandemic. We will have an accurate idea of the current global situati...
http://who.int/immunization/newsroom/PI_QAs/en/
*  Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Ra
... ndomized Double Blind Placebo Controlled Trial. All subjects received LAIV and then were randomized to LGG or placebo twice daily for 28 days. Future studies of probiotics as immune adjuvants may need to consider specifically examining vaccine naïve or seronegative subjects, target mucosal immune responses, or focus on groups known to have poor response to influenza vaccines. Keywords: Live attenuated Influenza vaccine, antibody responses, Probiotics, Lactobacillus GG. We conducted a proof of concept study to evaluate whether the probiotic Lactobacillus GG had any immune-adjuvant effect on serum influenza antibody titers and increased rates of seroconversion after administration of LAIV to healthy adults during a single influenza season. Table 2 Characteristics of Adverse events in the LGG and Placebo Groups and Immune Response to Immunization with Live Attenuated Influenza Vaccine. Table 3 Immune Response to Immunization with Live Attenuated Influenza Vaccine in the LGG vs. Taken together these s...
http://pubmedcentralcanada.ca/pmcc/articles/PMC3071884/?lang=en-ca
*  WHO | Pandemic influenza vaccine: WHO and international community make progress towards ensuring acc
Pandemic influenza vaccine: WHO and international community make progress towards ensuring access of developing countries. Media centre. Countries. Media centre. Media centre News News releases Previous years. Notes for the media Previous years. Pandemic influenza vaccine: WHO and international community make progress towards ensuring access of developing countries 22 March 2007. Geneva - The World Health Organization WHO is today reporting progress towards ensuring access to pandemic influenza vaccines for developing countries in the event of a pandemic and other vaccine-related aspects of influenza pandemic preparedness. "Most countries with resource constraints do not have the means to access influenza vaccines. If we are to be well-prepared for an influenza pandemic, it is essential that developing countries have access to vaccines. It also follows the launch of the Global pandemic influenza action plan to increase vaccine supply in October 2006. The International Federation of Pharmaceutical Manufacturer...
http://who.int/mediacentre/news/notes/2007/np13/en/
*  foodconsumer.org - Prenatal Influenza Vaccine May Prevent Flu in Infants
... Prenatal Influenza Vaccine May Prevent Flu in Infants Prenatal Influenza Vaccine May Prevent Flu in Infants 10/05/2010 13:34:00 David Liu Prenatal use of influenza vaccine may help young infants be protected against influenza or flu, according to a new study in the Feb 2011 issue of Archives of Pediatrics and Adolescent Medicine. The study showed that infants whose mothers received influenza vaccine were 41 percent less likely to acquire laboratory-confirmed influenza virus infection and 39 percent less likely to be hospitalized for influenza-like illness. then of Johns Hopkins Bloomberg School of Public Health in Baltimore and colleagues followed 1,269 women who delivered babies during one of three flu seasons and received information on maternal influenza vaccine and flu status in infants from 1,160 of them. These findings mean that maternal vaccination may provide extra protection for young infants. Infants younger than 6 months are not eligible for influenza vaccine; they, particularly those who are ...
http://foodconsumer.org/newsite/mobile/2/maternal_flu_vaccines_may_help_prevent_flu_in_infants_1005201008.html
*  Seasonal Influenza Vaccination Coverage — United States, 2009–10 and 2010–11
Seasonal Influenza Vaccination Coverage United States, 2009 10 and 2010 11. MMWR. Seasonal Influenza Vaccination Coverage United States, 2009 10 and 2010 11. This report is part of the second CDC Health Disparities and Inequalities Report CHDIR 12. This report provides an update on the progress of influenza vaccination coverage in the United States, by age, race/ethnicity, and risk status. Race was defined as white, black, Asian/Pacific Islander A/PI , American Indian/Alaska Native AI/AN , and other and multiple race. Vaccine coverage increased significantly among four groups of children: Hispanic and non-Hispanic whites, blacks, and those of other/multiple races. During the 2010 11 seasons, compared with non-Hispanic white children, coverage among Hispanic, Asian/Pacific Islander, and children of other and multiple races was higher Table. Coverage also was lower among Hispanic adults aged 18 49 and 50 64 years 27.1% and 41.9%, respectively than among non-Hispanic whites 31.6% and 45.7%, respe...
http://cdc.gov/mmwr/preview/mmwrhtml/su6203a11.htm?s_cid=su6203a11_x
*  Update: Influenza Vaccine Supply and Recommendations for Prioritization During the 2005--06 Influenz
... a Season. Update: Influenza Vaccine Supply and Recommendations for Prioritization During the 2005--06 Influenza Season. In response, prioritization has been implemented in previous years to ensure that enough vaccine is available for those at the highest risk for complications from influenza 3. The information in this report updates projections of influenza vaccine supply and previous recommendations for priority use of trivalent inactivated influenza vaccine TIV during the 2005--06 influenza season 4. MedImmune Vaccines, Inc., producer of live attenuated influenza vaccine LAIV, projects production of approximately 3 million doses. persons aged 65 years with comorbid conditions residents of long-term--care facilities persons aged 2--64 years with comorbid conditions persons aged 65 years without comorbid conditions children aged 6--23 months pregnant women health-care personnel who provide direct patient care household contacts and out-of-home caregivers of children aged 6 months. LAIV may be administered...
http://cdc.gov/MMWR/preview/mmwrhtml/mm5434a4.htm
*  CDC H1N1 Flu | Monovalent Influenza Vaccine Dosage, Administration, and Storage
Monovalent Influenza Vaccine Dosage, Administration, and Storage. Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options. 2009 H1N1 Monovalent Influenza Vaccine Dosage, Administration, and Storage December 28, 2009, 6:00 PM EDT This document has been revised to include updated information related to FDA approval of the GSK 2009 H1N1 monovalent influenza vaccine to be used in persons ages 18 years old and older and the expanded use of CSL 2009 H1N1 monovalent influenza vaccine to younger age groups. The intramuscular route is recommended for administering the influenza A H1N1 2009 monovalent inactivated vaccine. Live Attenuated Influenza Vaccine LAIV : Dosage, Administration, and Storage The 2009 H1N1 monovalent LAIV contains the same vaccine antigen as the inactivated vaccine. of doses Route Inactivated* Sanofi Pasteur 0.25 mL prefilled syringe 0 6 35 mos 2 Intra- muscular. Inactivated* Novartis Vaccines and Diagnostics Limi...
http://cdc.gov/h1n1flu/vaccination/dosage.htm
*  Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women - Tabula
... r View - ClinicalTrials.gov. Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women This study has been completed. Sponsor: University of Witwatersrand, South Africa Collaborator: Bill and Melinda Gates Foundation Information provided by Responsible Party : Michelle Groome, University of Witwatersrand, South Africa. Current Primary Outcome Measures ICMJE submitted: March 13, 2013. In this study we will use the following definitions to assess the humoral immune response to TIV: HAI titers 1:10 = seronegative; HAI titers 1:10 = seropositive; HAI titers 1:40 = sero-protective titers; and sero-conversion will be defined as HAI titers from 1:10 to 1:40 or 4-fold increase if pre-vaccination titers were 1:10. Original Primary Outcome Measures ICMJE. safety outcome measures of TIV Safety and tolerability of the study vaccine will be monitored by means of Adverse Events AEs and toxicity reports presenting laboratory and clinical data.Toxicities will be classified by the Divisio...
https://clinicaltrials.gov/ct2/show/record/NCT01812980
*  Seasonal Influenza Vaccination Coverage — United States, 2009–10 and 2010–11
. Seasonal Influenza Vaccination Coverage United States, 2009 10 and 2010 11. Skip directly to search Skip directly to A to Z list Skip directly to site content CDC Home. CDC 24/7: Saving Lives. Protecting People. Search The CDC. Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov. Morbidity and Mortality Weekly Report MMWR. MMWR. Share Compartir. Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation in the subject line of e-mail. Seasonal Influenza Vaccination Coverage United States, 2009 10 and 2010 11. Anne F. McIntyre, PhD Amparo G. Gonzalez-Feliciano, MPH Leah N. Bryan, MPH, Tammy A. Santibanez, PhD Walter W. Williams, MD James A. Singleton, PhD National Center for Immunization and Respiratory Diseases, CDC. Corresponding author: Anne ...
http://cdc.gov/mmwr/preview/mmwrhtml/su6203a11.htm?s_cid=su6203a11_w
*  Estimated Influenza Vaccination Coverage Among Adults and Children --- United States, September 1-
... -November 30, 2004. Estimated Influenza Vaccination Coverage Among Adults and Children --- United States, September 1--November 30, 2004. In addition, new questions for adults and children were asked to determine 1 the month and year of the most recent influenza vaccination, 2 whether persons were vaccinated for influenza during the 2003--04 influenza season, 3 the primary reason vaccination was not received, and 4 whether the respondent or a child in the household was in one of the following ACIP-designated priority groups for vaccination: persons aged 65 years or aged 6--23 months, persons aged 2--64 years with one or more conditions that increase risk for influenza complications, health-care workers with patient contact, and household contacts of children aged 6 months*. Among adults in all priority groups, 34.8% reported receiving an influenza vaccination during September 1--November 30, compared with 4.4% of adults aged 18--64 years who were not in a priority group Table 1. Among persons aged 65 year...
http://cdc.gov/mmwr/preview/mmwrhtml/mm5349a1.htm
*  Live attenuated influenza vaccine
1 It is an attenuated vaccine, unlike most influenza vaccines, which are inactivated vaccine s. Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza Supplemental Recommendations of the Advisory Committee on Immunization Practices ACIP. All other FDA-approved lots were inactivated virus vaccines. In Canada, the National Advisory Committee on Immunization NACI, the group that advises the Public Health Agency of Canada, currently recommends that everyone aged 2 to 64 years be encouraged to receive annual influenza vaccination, and that children between the age of 6 and 24 months, and their household contacts, should be considered a high priority for the flu vaccine. Centers for Disease Control and Prevention CDC Advisory Committee on Immunization Practices ACIP recommended vaccination for all children and teenagers between six months and 18 years of age. suggest that FluMist may be equal to or more effective than injected influenza vaccines in children aged 6–71 months and in children...
https://en.wikipedia.org/wiki/Live_attenuated_influenza_vaccine
*  Search of: H1n1 | "Influenza, Human" - List Results - ClinicalTrials.gov
Conditions: Influenza; Pandemic Influenza; Influenza A Virus, H1N1 Subtype. Intervention: Biological: A/H1N1 pandemic influenza vaccine non- adjuvanted. Interventions: Biological: Swine A/H1N1 influenza vaccine split virion, inactivated ; Biological: Swine A/H1N1 influenza vaccine split virion, inactivated + Adjuvant ; Biological: Swine A/H1N1 influenza vaccine split virion, inactivated + adjuvant. Interventions: Biological: Swine A/H1N1 influenza vaccine split virion, inactivated ; Biological: Swine A/H1N1 influenza vaccine split virion, inactivated + Adjuvant. 4 Completed A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly. Interventions: Biological: Swine A/H1N1 influenza vaccine split virion, inactivated ; Biological: Swine A/H1N1 influenza vaccine split virion, inactivated. 7 Completed A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults. Intervention: Biological: Swine A/H1N1 influenza vaccine split virion, inactivated. Conditi...
https://clinicaltrials.gov/ct2/results?term=H1n1&cond="Influenza, Human"
*  FluMist (Influenza Virus Vaccine) Drug Information: Description, User Reviews, Drug Side Effects, In
FluMist Influenza Virus Vaccine Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList. Drugs A-Z. flumist influenza virus vaccine side effects drug center. flumist influenza virus vaccine drug. FluMist User Reviews >> FluMist. Drug Description FluMist Quadrivalent Influenza Vaccine Live, Intranasal Patient Information. DRUG DESCRIPTION FluMist Quadrivalent Influenza Vaccine Live, Intranasal is a live quadrivalent vaccine for administration by intranasal spray. The influenza virus strains in FluMist Quadrivalent are a cold-adapted ca i.e., they replicate efficiently at 25 C, a temperature that is restrictive for replication of many wild-type influenza viruses ; b temperature-sensitive ts i.e., they are restricted in replication at 37 C Type B strains or 39 C Type A strains, temperatures at which many wild-type influenza viruses grow efficiently ; and c attenuated att i.e., they do not produce classic influenza-like illness in the ferret model of human ...
http://rxlist.com/flumist-drug.htm
*  Technically Speaking: One Dose or Two? How Many Doses of Influenza Vaccine Do Children Need in the 2
Technically Speaking: One Dose or Two. How Many Doses of Influenza Vaccine Do Children Need in the 2012-13 Season. About IAC. Clinic Resources Storage Handling. Clinic Resources. Storage Handling. Importance of Vaccines Vaccine Safety. IAC Home. Technically Speaking. Technically Speaking. TECHNICALLY SPEAKING. How Many Doses of Influenza Vaccine Do Children Need in the 2012-13 Season. For several years in a row, the Centers for Disease Control and Prevention CDC has adjusted its vaccination recommendations regarding which children need two doses of influenza vaccine. Children age 9 years and older should receive only one dose of influenza vaccine. Children age 6 months through 8 years should receive two doses of influenza vaccine spaced four weeks or more apart if:. They have not received at least two doses of seasonal influenza vaccine since July 1, 2010. The CDC has also developed an alternative approach that healthcare providers can use for children with WELL-DOCUMENTED immunization histories e.g., those m...
http://immunize.org/technically-speaking/20120901.asp
*  Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine -- ScienceDa
... ily. Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine. Date: October 5, 2009 Source: NIH/National Institute of Allergy and Infectious Diseases Summary: Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising. Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health. NIH/National Institute of Allergy and Infectious Diseases. "Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine." ScienceDaily. NIH/National Institute of Allergy and Infectious Diseases. Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine. Retrieved October 4, 2015 from www.sciencedaily.com/releases/2009/09/090921134857.htm NIH/National Institute of Allergy and Infectious Diseases. "Early Results: In Children, 2009 H1N1 Influen...
http://sciencedaily.com/releases/2009/09/090921134857.htm
*  FDA approves Flublok, a trivalent influenza vaccine not made with eggs
... Click to Print. FDA approves Flublok, a trivalent influenza vaccine not made with eggs. By Michael Johnsen. SILVER SPRING, Md. The Food and Drug Administration on Wednesday approved Protein Sciences' Flublok, the first trivalent influenza vaccine made using an insect virus baculovirus expression system and recombinant DNA technology. This approval represents a technological advance in the manufacturing of an influenza vaccine, stated Karen Midthun, director of the FDA s Center for Biologics Evaluation and Research. The new technology offers the potential for faster startup of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus. Unlike current flu vaccines, Flublok does not use the influenza virus or eggs in its production. Flublok s novel manufacturing technology allows for production of large quantities of the influenza virus protein, hemagglutinin the active ingredient in all inactivated influenza vaccines ...
http://drugstorenews.com/print/519086
*  Influenza vaccination coverage among health-care personnel - 2011-12 influenza season, United States
... BioMedSearch. Home. Advanced Search. Tools. Search Tutorial. Login. Create Free Account. Document Detail. Influenza vaccination coverage among health-care personnel - 2011-12 influenza season, United States. MedLine Citation:. PMID: 23013720 Owner: NLM Status: In-Data-Review. Abstract/OtherAbstract:. Influenza vaccination of health-care personnel HCP is recommended by the Advisory Committee on Immunization Practices ACIP. Vaccination of HCP can reduce morbidity and mortality from influenza and its potentially serious consequences among HCP, their family members, and their patients. To provide timely estimates of influenza vaccination coverage and related data among HCP for the 2011-12 influenza season, CDC conducted an Internet panel survey with 2,348 HCP during April 2-20, 2012. This report summarizes the results of that survey, which found that, overall, 66.9% of HCP reported having had an influenza vaccination for the 2011-12 season. By occupation, vaccination coverage was 85.6% among physicians, 77.9...
http://biomedsearch.com/nih/Influenza-vaccination-coverage-among-health/23013720.html
*  How Influenza (Flu) Vaccines Are Made | Seasonal Influenza (Flu) | CDC
How Influenza Flu Vaccines Are Made. Seasonal Influenza Flu. Submit Search The CDC. Submit Search The CDC. Influenza Flu. Seasonal Influenza Flu. 2015-2016 Flu Season. Influenza Viruses. Types of Influenza Viruses. Flu Season. Prevention - Flu Vaccine. Approved Influenza Vaccines. How Flu Vaccines Are Made. Selecting Viruses for the Seasonal Influenza Vaccine. Guidelines for Flu Vaccination. Antiviral Drug Supply. Information for Health Care Professionals. Taking Care of Yourself. Recommendations for Obstetric Health Care Providers Related to Use of Antiviral Medications. 2011-12 Flu Season, National Immunization Survey and National Flu Survey, March 2012. 2009–10 Flu Season, Final State-Level Seasonal and H1N1 Flu Vaccination Estimates. 2009-10 Flu Season, Influenza Vaccination Among Women with a Recent Live Birth PRAMS. 2008–09 Flu Season, Flu Vaccination Estimates, Children Aged 6–23 Months. See Influenza Vaccines United States, 2013 14 Influenza Season for specific indications. There are many different ma...
http://cdc.gov/flu/protect/vaccine/how-fluvaccine-made.htm
*  Influenza Immunization Statistics - Minnesota Dept. of Health
Influenza Immunization Statistics Statistics on influenza immunization rates are collected via the Behavioral Risk Factor Surveillance System. Minnesota data Influenza Pneumococcal Vaccination Rates for Adults 65 and Older Graph of influenza and pneumococcal vaccination rates from the Behavior Risk Factor Survey Surveillance BRFSS system. State-Specific Influenza Vaccination Coverage Among Adults Aged 18 Years United States, 2003-04 and 2005-06 Influenza Seasons Data from the 2004 and 2006 BRFSS is used to estimate influenza vaccination coverage among adults by age, risk group and race/ethnicity for the 2005-06 influenza season, and the difference in coverage between the 2005-06 and 2003-04 seasons. Attention: Non-MDH link Influenza Vaccination Coverage Among Children Aged 6-23 Months. United States, 2005-06 Influenza Season Data from the 2006 National Immunization Survey NIS is used to estimate influenza vaccination coverage among children aged 6-23 months for the 2005-06 influenza season. Attention: Non-MDH...
http://health.state.mn.us/divs/idepc/diseases/flu/stats/immlevels.html
*  Influenza A H1N1 Monovalent Vaccine (Influenza A H1N1 Monovalent Vaccine) Drug Information: Medicati
Influenza A H1N1 Monovalent Vaccine Influenza A H1N1 Monovalent Vaccine Drug Information: Medication Guide and Patient Information - Prescribing Information at RxList. Drugs A-Z. Pill Identifier. influenza a h1n1 monovalent vaccine influenza a h1n1 monovalent vaccine side effects drug center. influenza a h1n1 monovalent vaccine influenza a h1n1 monovalent vaccine drug - medication guide and patient information. Recommended Topic Related To: Influenza A H1N1 Monovalent Vaccine. FDA Approves First Adjuvanted Vaccine for Bird Flu "The U.S. Food and Drug Administration today approved the first adjuvanted vaccine for the prevention of H5N1 influenza, commonly known as avian or bird flu. The vaccine, Influenza A H5N1 Virus Monovalent Vaccine, Adjuvanted, is for use in peopl"... Influenza A H1N1 Monovalent Vaccine. PATIENT INFORMATION Inform vaccine recipients or guardians that Influenza A H1N1 2009 Monovalent Vaccine contains killed viruses and cannot cause influenza. Inform vaccine recipients or guardians that the...
http://rxlist.com/influenza-a-h1n1-monovalent-vaccine-drug/medication-guide.htm
*  Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza
... Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation in the subject line of e-mail. Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza Supplemental Recommendations of the Advisory Committee on Immunization Practices ACIP. Prepared by Scott A. Harper, M.D. 1 Keiji Fukuda, M.D. 1 Nancy J. Cox, Ph.D. 1 Carolyn B. Bridges, M.D. 2 1 Division of Viral and Rickettsial Diseases National Center for Infectious Diseases 2 Epidemiology and Surveillance Division National Immunization Program. The material is this report originated in the National Center for Infectious Diseases, James M. Hughes, M.D., Director, and the Division of Viral and Rickettsial Diseases, James LeDuc, Ph.D., Director; and the National Immunization Program, Walter A. Orenstein, M.D., Director, and Epidemiology and Surveillance Division, Melinda Wharton, M.D., Director. Summary. This report summarize...
http://cdc.gov/mmwr/preview/mmwrhtml/rr5213a1.htm
*  Influenza Vaccine - Care Guide
... All Consumer Professional Pill ID Interactions News FDA Alerts Approvals Pipeline Clinical Trials Care Notes Encyclopedia Dictionary Natural Products. Influenza Vaccine. Influenza Vaccine. What is the influenza vaccine. The influenza vaccine is an injection or nasal spray given to help prevent influenza flu. What are the types of influenza vaccines. It is made from influenza viruses that are weak, but still alive. When should I get the influenza vaccine. Get the influenza vaccine as soon as it is available. Children between 6 months and 8 years old need 2 vaccines during the first year they get it. The 2 vaccines should be given 4 or more weeks apart. Who should get the flu shot. Anyone who has chronic health problems, such as asthma, diabetes, or blood disorders. Anyone who has a weak immune system. Who should not get the flu shot. Anyone who has an egg allergy should ask the healthcare provider if it is safe to get the flu shot. Anyone who has had an allergic reaction to the flu shot. Anyone who receiv...
http://drugs.com/cg/influenza-vaccine.html
*  Flu Vaccine Causes, Symptoms, Treatment - Future Flu Vaccines - eMedicineHealth
... Topics A-Z. Slideshow Pictures. Medical Dictionary. cold flu center. Natural Cold and Flu Remedies Slideshow Pictures. Indications for the Nasal-Spray Flu Vaccine FluMist, Live Attenuated Influenza Virus or LAIV. Side Effects or Reactions to Flu Vaccines and Flu Vaccine Safety Seasonal and Pandemic. Effectiveness of Seasonal and Pandemic Flu Vaccines. Viral Strains and Producers of the Seasonal Flu Vaccines for 2014-2015. Where to Go to Obtain the Flu Vaccine Future Flu Vaccines. Flu Vaccine Topic Guide. Future Flu Vaccines. United States. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/acip/index.html. United States. Centers for Disease Control and Prevention. "Children, the Flu, and the Flu Vaccine." Aug. http://www.cdc.gov/flu/protect/children.htm. United States. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-flu.pdf. United States. Centers for Disease Control and Prevention. "Influenza Vaccines -- United States, 2014-15 Influenza...
http://emedicinehealth.com/flu_vaccine/page12_em.htm
*  Predictors of Seasonal Influenza Vaccination During Pregnanc... : Obstetrics & Gynecology
Predictors of Seasonal Influenza Vaccination During Pregnanc... Predictors of Seasonal Influenza Vaccination During Pregnanc... Text sizing: A. Supported by the Centers for Disease Control and Prevention's Vaccine Safety Datalink 200-2002-00732 through America's Health Insurance Plans. Women completed a survey assessing knowledge, attitudes, and beliefs about vaccination based on the Health Belief Model by telephone and were then followed to determine vaccination status by the end of the 2010–2011 influenza season. 20–22 Health Belief Model factors associated with higher vaccination rates during pregnancy include recommendations from a health care provider, perceived effectiveness of influenza vaccinations, and perceived risk of influenza infection. 15,24–26,28,29 Factors often associated with lower vaccination rates during pregnancy include black or Hispanic race or ethnicity; perception that the vaccine had not been adequately tested; concerns about vaccine effects on maternal or fetal health; and lack of k...
http://journals.lww.com/greenjournal/Fulltext/2013/04000/Predictors_of_Seasonal_Influenza_Vaccination.8.aspx
*  Prevention and Control of Seasonal Influenza with Vaccines
For the 2013 14 influenza season, it is expected that trivalent live attenuated influenza vaccine LAIV3 will be replaced by a quadrivalent LAIV formulation LAIV4. These vaccines include the following: A quadrivalent live attenuated influenza vaccine LAIV4; Flumist Quadrivalent is expected to replace the trivalent LAIV3 formulation. A quadrivalent inactivated influenza vaccine IIV4; Fluzone Quadrivalent will be available, in addition to the previous trivalent formulation. Immunogenicity, Efficacy, and Effectiveness of IIV Inactivated vaccines, which are administered by intramuscular or intradermal injection, contain nonreplicating virus. Safety of Influenza Vaccines Inactivated Influenza Vaccines Children: A large postlicensure population-based study assessed IIV3 safety in 251,600 children aged 18 years including 8,476 vaccinations in children aged 6 through 23 months enrolled in one of five health-care organizations within the Vaccine Safety Datalink VSD http://www.cdc.gov/vaccinesafety/activities/vsd.html d...
http://cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm?s_cid=rr6207a1_w.htm
*  School-based influenza vaccine delivery, vaccination rates, and healthcare use in the context of a u
... niversal influenza immunization program: An ecological study. Article School-based influenza vaccine delivery, vaccination rates, and healthcare use in the context of a universal influenza immunization program: An ecological study. Jeffrey C Kwong Institute for Clinical Evaluative Sciences Message author. Impact Factor: 3.62. We examined the impact of school-based delivery on vaccination rates and healthcare use of the entire population over seven influenza seasons 2000-2007 using population-based survey and health administrative data. In the context of universal influenza vaccination, school-based delivery is associated with higher vaccination rates and modest reductions in healthcare use in school-age children. School-Based Influenza Vaccination: Parents’ Perspectives. ABSTRACT: School-age children are important drivers of annual influenza epidemics yet influenza vaccination coverage of this population is low despite universal publicly funded influenza vaccination in Alberta, Canada. We explored parents...
http://researchgate.net/publication/41172915_School-based_influenza_vaccine_delivery_vaccination_rates_and_healthcare_use_in_the_context_of_a_universal_influenza_immunization_program_An_ecological_study
*  WHO | OBJECTIVE 1. Increase in seasonal vaccine use
Increase in seasonal vaccine use. Global action plan for influenza vaccines. Global action plan for influenza vaccines GAP advisory group GAP objectives Resources News. Increase in seasonal vaccine use The first GAP approach is to encourage countries to increase their seasonal vaccine use. Increase use of seasonal influenza vaccine. surveillance of seasonal disease burden assess current and planned seasonal vaccine use, and potential pandemic vaccine demand strengthen national immunization advisory committees assess and strengthen national capacity to deploy pandemic vaccine establish an H5N1 influenza vaccine stockpile develop tools to estimate the impact and cost-effectiveness of different scenarios with limited pandemic influenza vaccine availability promote activities to ensure equitable access for all Member States to pandemic influenza vaccines. Two global surveys Mapping the landscape-current and future use of influenza vaccine 2007 and Survey for the Global mapping of seasonal influenza vaccine 2010 m...
http://who.int/influenza_vaccines_plan/objectives/objective1/en/
*  An update on influenza vaccination in patients with egg alle... : Current Opinion in Pediatrics
... Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. Current Opinion in Pediatrics Wolters Kluwer Health Logo. An update on influenza vaccination in patients with egg alle... A A You could be reading the full-text of this article now if you... If you have access to this article through your institution, you can view this article in. An update on influenza vaccination in patients with egg allergy Gruenberg, David A.; Shaker, Marcus S. Recent findings: Because of concern regarding the egg protein content in the influenza virus vaccine, pediatricians have in the past typically taken a conservative approach of avoiding influenza vaccination in egg-allergic patients. Subsequently, it was shown that the influenza vaccine could be safely administered to patients who had negative skin testing to the vaccine. Summary: In considering vaccination in a patient with a history of e...
http://journals.lww.com/co-pediatrics/Abstract/2011/10000/An_update_on_influenza_vaccination_in_patients.13.aspx
*  .. A $707 million investment in cell-based influenza vaccine
A cell-based vaccine is expected to shorten by a few weeks the time required to produce a vaccine for a new influenza virus strain No cell-based influenza vaccine is currently licensed for use in the US Cell-based influenza vaccines use the same technology developed 50 years ago for egg-grown vaccine, with the exception that the virus is propagated in a different host Inactivated influenza vaccine is not very good – it is 59% effective in individuals 18-65 years of age We need a completely different influenza virus vaccine, not a retread of the existing process. Influenza vaccines that can protect against all viral strains now seem possible, and these vaccines will probably not be based on growing influenza viruses in eggs or cell culture. I suspect that contemporary influenza vaccines produced in eggs or cell culture will be replaced with new vaccines within the next decade. Even more money is at stake – according to CIDRAP, “Novartis is one of five companies that received sizable HHS contracts in 2006 to de...
http://virology.ws/2011/12/16/a-707-million-investment-in-cell-based-influenza-vaccine/
*  Misconceptions about Seasonal Flu and Flu Vaccines | Seasonal Influenza (Flu) | CDC
Misconceptions about Seasonal Flu and Flu Vaccines. Seasonal Influenza Flu. Submit Search The CDC. Submit Search The CDC. Influenza Flu. Seasonal Influenza Flu. 2015-2016 Flu Season. Influenza Viruses. Flu Season. Approved Influenza Vaccines. How Flu Vaccines Are Made. Selecting Viruses for the Seasonal Influenza Vaccine. Information for Health Care Professionals. Taking Care of Yourself. 2011-12 Flu Season, National Immunization Survey and National Flu Survey, March 2012. The effectiveness of vaccination against influenza in healthy working adults. Flu can be a serious disease, particularly among young children, older adults, and people with certain chronic health conditions, such as asthma, heart disease or diabetes. Reactions to nasal spray flu vaccine: People also may have mild reactions to the nasal spray vaccine. Top of Page What about people who get a seasonal flu vaccine and still get sick with flu-like symptoms. Top of Page Misconceptions about Flu Vaccine Effectiveness Are there really benefits to g...
http://cdc.gov/flu/about/qa/misconceptions.htm?s_cid=cs_000
*  influenza virus vaccine (nasal) | Health Encyclopedia | Keene | Dartmouth-Hitchcock
influenza virus vaccine nasal. Cheshire Medical Center/Dartmouth-Hitchcock Keene. influenza virus vaccine nasal. The nasal influenza virus vaccine is a "live virus" vaccine. For at least 21 days after receiving nasal influenza virus vaccine, avoid close contact with anyone who has a weak immune system caused by disease such as cancer, HIV, or AIDS, or by certain medicines such as steroids, cancer chemotherapy, or radiation treatment. A person with a weak immune system can become ill if they have close contact with you after you have recently received an influenza vaccine. Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive influenza virus vaccine in the future, you will need to tell your doctor if the previous dose caused any side effects. Nasal influenza virus live virus vaccine may cause you to have mild flu-like symptoms. However, you may have flu-like symptoms at any time during flu season that may be caused by strains of influenza virus that are not c...
http://cheshire-med.com/health_wellness/health_encyclopedia/d04892a1
*  JAMA Network | JAMA Pediatrics | Influenza Vaccine Effectiveness Among Children 6 to 59 Months of
Influenza Vaccine Effectiveness Among Children 6 to 59 Months of Age During 2 Influenza Seasons: A Case-Cohort Study. COMMENT. We compared vaccination status of laboratory-confirmed influenza cases with a cluster sample of children from a random sample of practices in 3 counties subcohort during the 2003-2004 and 2004-2005 seasons. The objective of our study was to use a case-cohort study method, which selects control subjects who are representative of the general population for comparison with cases, to measure the effectiveness of trivalent inactivated influenza vaccine in preventing laboratory-confirmed influenza-associated medical visits. *The same primary care practices were used for cases and subcohort within each county and year. During the same 2 influenza seasons, we conducted an analogous, prospective study of laboratory-confirmed influenza-related outpatient visits among county children aged 6-23 months or 24-59 months presenting to selected primary care practices within the 3 counties: 1 practice ...
http://archpedi.jamanetwork.com/article.aspx?articleid=380239
*  NACCHO to Support Influenza Vaccination Efforts With Donation of Up to One Million Doses of ... ( WA
Home Biology Medicine Technology Products News Definition Dictionary Movies Links Tags Search RSS Navigation Links Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary HOME >> MEDICINE >> NEWS NACCHO to Support Influenza Vaccination Efforts With Donation of Up to One Million Doses of FluMist(R) ...WASHINGTON Dec. 10 /- The National Association of County... NACCHO will make these donated doses of vaccine available to selec... NACCHO is pleased to partner with MedImmune to help increase the ... Public health guidelines on annual influenza vaccination are broad... http://www.bio-medicine.org/inc/biomed/medicine-news.asp http://feeds.bio-medicine.org/latest-medical-news Date:12/10/2008 WASHINGTON, Dec. 10 /PRNewswire/ -- The National Association of County and City Health Officials (NACCHO) today announced a donation of up to one million doses of FluMist(R) (Influenza Virus Vaccine Live, In...
http://bio-medicine.org/medicine-news-1/NACCHO-to-Support-Influenza-Vaccination-Efforts-With-Donation-of-Up-to-One-Million-Doses-of-FluMist-28R-29-31808-1/
*  Home Page | Vivaldi Biosciences Inc. | Influenza Vaccines
Influenza Vaccines. Vivaldi Biosciences is a clinical-stage biotechnology company developing live attenuated influenza vaccines LAIVs to address the most pressing public health issues of influenza: the need for a rapid and effective response to emerging pandemics with vaccines that are easily administered, safe and protective, and the need for vaccines that protect the most vulnerable populations seniors and young children against seasonal influenza. These age groups suffer disproportionately from influenza and its serious complications, but are poorly served by conventional influenza vaccines. Vivaldi s LAIV technology platform uses the biology of the influenza NS1 protein to provide a new vaccine approach with the potential for superior efficacy and protection. Instead of blocking interferon, Vivaldi s LAIVs promote interferon production and immunity in the recipient. Administered as a nasal spray, Vivaldi s LAIVs generate a robust immune response in the nasal passages as a first line of defense at the natu...
http://vivaldibiosciences.com/
*  Afluria (Influenza Virus Vaccine) Patient Information: Side Effects and Drug Images at RxList
Afluria Influenza Virus Vaccine Patient Information: Side Effects and Drug Images at RxList. Drugs A-Z. Pill Identifier. afluria influenza virus vaccine side effects drug center. afluria influenza virus vaccine drug - patient side effects and images. Afluria. Afluria Patient Information Including Side Effects Brand Names: Afluria 2012-2013, Afluria Preservative-Free 2012-2013, Fluarix 2012-2013, FluLaval 2012-2013, Fluvirin 2012-2013, Fluvirin Preservative-Free 2012-2013, Fluzone 2012-2013, Fluzone High-Dose 2012-2013, Fluzone Intradermal 2012-2013, Fluzone Preservative-Free 2012-2013, Fluzone Preservative-Free Pediatric 2012-2013. What is influenza virus vaccine Afluria. What are the possible side effects of influenza virus injectable vaccine. What other drugs will affect influenza virus injectable vaccine. What is influenza virus vaccine Afluria. The injectable influenza virus vaccine flu shot is a "killed virus" vaccine. Becoming infected with influenza is much more dangerous to your health than receiving ...
http://rxlist.com/afluria-drug/patient-images-side-effects.htm
*  FDA Approves First Trivalent Influenza Vaccine Made Using Recombinant Technology
... CME. Journals. Patient Care. Medical School & Residency. Practice Management. Advocacy. Events. About. AAFP News. Contact. Home. Search AAFP News. Search AAFP.org AAFP News. Sign In or. My Account. My Account. My Account. . Sign Out. Welcome. Shop. View Cart 0. Menu. AAFP News AAFP Leader Voices Blog. Fresh Perspectives Blog. News From 2015 COD and FMX. Health of the Public. Practice Professional Issues. Government Medicine. Physician Education Development. As We See It: Voices From the AAFP. Family Medicine for America's Health. Inside the Academy. 2014: The Year in Review. News From 2014 AAFP Congress Assembly. Chapter Spotlight. News in Brief. About AAFP News. In Memoriam. News Archives. FDA Approves First Trivalent Influenza Vaccine Made Using Recombinant Technology Omitting Reliance on Eggs, Flu Virus Allows Speedier Production January 23, 2013 04:55 pm Matt Brown. The FDA's recent approval of a trivalent seasonal influenza vaccine made using novel manufacturing technology marks a significant milest...
http://aafp.org/news/health-of-the-public/20130123flublokapproved.html
*  Fda Approves Four-strain Sanofi Influenza Vaccine
... Web Toolbar by Wibiya. Login. Sign Up. Edit Profile. Edit Comunitiees. Account Settings. Help Center. Log Out close. Invite Friends from:. Invite Friends from:. Invite friends:. close. Share all the articles you read with your Twitter followers. New to Comunitee. or Sign Up with Email. Top Stories. World. US. Business. Politics. Entertainment. Tech. Sports. Health. Lifestyle. Viral. My Categories. ADD A CATEGORY. Health INFLUENZA VACCINE Latest News. INFLUENZA VACCINE. JUN 10, 2013 - Yahoo. News A Must Read -. Share. FDA approves four-strain Sanofi influenza vaccine. By Ransdell Pierson Reuters - French drugmaker Sanofi SA said the U.S. Food and Drug Administration had approved its four-strain influenza vaccine, which is meant to provide better protection from infection than traditional three-strain flu vaccines. The Fluzone Quadrivalent vaccine is licensed for adults, adolescents and children 6 months and older, and will be available in the upcoming 2013-2014 flu season, the company said on Monday. The ...
http://comunitee.com/latest-news/health/fda-approves-four-strain-sanofi-influenza-vaccine-44776.12586502.html
*  JAMA Network | JAMA | Live Attenuated or Inactivated Influenza Vaccines and Medical Encounters fo
Live Attenuated or Inactivated Influenza Vaccines and Medical Encounters for Respiratory Illnesses Among US Military Personnel. The Defense Medical Surveillance System DMSS is a large relational database containing longitudinal data about demographic characteristics, occupations, immunizations, and medical encounters for US military service members. The incidence rate of pneumonia and influenza per 1000 person-years was calculated for the unimmunized, TIV-immunized, and LAIV-immunized groups. The total cohorts were 1 061 728 for 2004-2005, 1 041 264 for 2005-2006, and 1 067 959 for 2006-2007 Figure 1. Total, vaccine-naive, and propensity-matched cohorts were grouped together according to immunization status. Propensity-score matching was performed among 3 groups: trivalent inactivated vaccine TIV vs unimmunized, live attenuated influenza vaccine LAIV vs unimmunized, and TIV vs LAIV. The incidence rate of health care encounters for pneumonia and influenza was highest in the unimmunized group each season 19.4, ...
http://jama.jamanetwork.com/article.aspx?articleid=183495
*  WHO | Clinical evaluation of influenza vaccines
Clinical evaluation of influenza vaccines. Data. Immunization, Vaccines and Biologicals. Immunization, Vaccines and Biologicals Vaccines and diseases Global Vaccine Action Plan WHO policy recommendations SAGE Immunization schedules Position papers Advisory committees. Monitoring and surveillance Surveillance and burden Monitoring systems Data and statistics Resources. Table for pandemic and potentially pandemic influenza vaccines xls, 652kb. Table for seasonal influenza vaccines xls, 751kb. Information about immunogenicity, as well as efficacy or effectiveness when available of human influenza vaccines is presented on two separate tables for pandemic/”pre-pandemic” and seasonal vaccines. The table on pandemic/”pre-pandemic” vaccines, compiled by WHO starting in 2007 upon request of its Member States and of various stakeholders in the area of pandemic preparedness, provides an abbreviated description of data provided in preliminary form to WHO on the status of recent development of vaccines directed against in...
http://who.int/immunization/research/development/flu_trials_tables/en/
*  Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal Questions and Answers
Influenza A H1N1 2009 Monovalent Vaccine Live, Intranasal Questions and Answers. FDA U.S. Follow FDA. Search FDA. Vaccines, Blood & Biologics. Vaccines, Blood & Biologics. Vaccines, Blood & Biologics. January 13, 2010 What information did FDA use to support the approval of the Intranasal Influenza A H1N1 2009 Monovalent Live Attenuated Vaccine. FDA approved all of the Influenza A H1N1 2009 vaccines as a strain change to each manufacturer s FDA-approved seasonal influenza vaccine. The safety and efficacy demonstrated for the seasonal influenza vaccine, FluMist, supported the licensure of the Intranasal Influenza A H1N1 2009 Monovalent Live Attenuated Vaccine produced using the same process as for seasonal vaccine. How is the Intranasal Influenza A H1N1 2009 Monovalent Live Attenuated Influenza Vaccine LAIV different from the Influenza A H1N1 2009 Monovalent inactivated influenza vaccine. LAIV contains attenuated weakened virus. LAIV is approved for individuals 2 through 49 years of age. Some inactivated influe...
http://fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm197513.htm
*  Factors affecting influenza vaccination among non-instutionalized elderly persons in Hong Kong - Op
... enThesis. Factors affecting influenza vaccination among non-instutionalized elderly persons in Hong Kong. Uncorrected OCR Abstract of thesis entitled Factors affecting Influenza Vaccination among Non-instutionalized Elderly Persons in Hong Kong Submitted by LAU Lam For the Degree of Master of Medical Science Geriatric Medicine, Department of Medicine at The University of Hong Kong in August 2005 Background: Influenza vaccination has been confirmed as both clinically and cost-effectively powerful in reducing the mortality and morbidity of elderly from influenza complications in recent studies. This study aims at exploring the factors that influence Hong Kong elderly persons on influenza vaccine uptake. The association between self-reported influenza vaccination status in current year and several sociodemographic, perception, health status, knowledge, source of advice, cognitive, ADL function as well as influence of SARS and Avian Flu outbreak variables was assessed by logistic regression. The associations ...
http://openthesis.org/documents/Factors-affecting-influenza-vaccination-among-511341.html
*  Notice to Readers: Expansion of Eligibility for Influenza Vaccine Through the Vaccines for Childre
... n Program. Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation in the subject line of e-mail. Notice to Readers: Expansion of Eligibility for Influenza Vaccine Through the Vaccines for Children Program. On June 20, 2002, the Advisory Committee on Immunization Practices ACIP adopted a resolution expanding the group of children eligible for influenza vaccine coverage under the Vaccines for Children VFC program. The resolution extends VFC coverage for influenza vaccine to all VFC-eligible children aged 6--23 months and VFC-eligible children aged 2--18 years who are household contacts of children aged 2 years. The resolution becomes effective on March 1, 2003, for vaccine to be administered during the 2003--04 influenza vaccination season and subsequent seasons. ACIP is expanding VFC influenza coverage because children aged 23 months are at substantially increased risk for influenza-related ...
http://cdc.gov/MMWR/preview/mmwrhtml/mm5138a7.htm
*  Novartis's Influenza Vaccine Program | BioPharm International
Novartis's Influenza Vaccine Program. BioPharm International. Novartis's Influenza Vaccine Program The global head of technical operations at Novartis talks about new technologies for vaccine development and manufacturing. Novartis recently built a plant for cell-based manufacture of influenza vaccine in Holly Springs, North Carolina. In this interview, Matthew Stober, global head of technical operations for Novartis, talks about the company's plans for the new facility and new technologies for vaccine development and manufacturing. Novartis recently built a plant for cell-based manufacture of influenza vaccine in Holly Springs, North Carolina. What will be produced at the facility. Stober: Novartis opened its Holly Springs, North Carolina facility in November 2009 in collaboration with the US Department of Health and Human Services HHS. The facility has been designed and constructed with the support of the US government to produce seasonal flu cell-culture vaccine, pre-pandemic and pandemic influenza vaccine...
http://biopharminternational.com/novartiss-influenza-vaccine-program
*  “Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 p
“Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?” - Springer. “Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?”. W Goethe University Clinic Frankfurt/Main. W Goethe University Clinic Frankfurt/Main. W Goethe University Clinic Frankfurt/Main. W Goethe University Clinic Frankfurt/Main. W Goethe University Clinic Frankfurt/Main. Keywords Trivalent influenza vaccination Restricted immune response to H1N1v High influenza B and A/H3N2 seropositivity rates Hemagglutination inhibition assay. Share Share this content on Facebook Share this content on Twitter Share this content on LinkedIn. Related Content. Eur J Clin Microbiol Infect Dis 28 9 :1077–1086. PubMed. CrossRef. PubMed. CrossRef. PubMed. Med Microbiol Immunol 191 3–4 :183–185. PubMed. J Infect Dis 204 6 :845–853. PubMed. CrossRef. P...
http://link.springer.com/article/10.1007/s00430-012-0259-9
*  WHO | Workshop on Enhancing Communication around Influenza Vaccination (WEECIV)
Workshop on Enhancing Communication around Influenza Vaccination WEECIV. Access Home Alt+0. Navigation Alt+1. Search Search the WHO .int site. Advanced search. Navigation Home. Health topics. Data. Media centre. Publications. Countries. Programmes. Governance. RSS Feed. Youtube. Twitter. Facebook. Google +. iTunes. Play Store. Global action plan for influenza vaccines. Global action plan for influenza vaccines GAP advisory group GAP objectives Resources News. Workshop on Enhancing Communication around Influenza Vaccination WEECIV Centers for Disease Control and Prevention, Atlanta, USA, 11-13 June 2013 Introduction To ensure rapid and equitable access to influenza vaccines in the event of a pandemic, WHO’s Global Action Plan for Influenza Vaccines GAP promotes the expansion of influenza vaccine production capacity, including the establishment of new production facilities in countries and regions previously lacking capacity. The Workshop on Enhancing Communication around Influenza Vaccination will directly sup...
http://who.int/influenza_vaccines_plan/news/workshop_communication_influenza_vaccination_11_13_june_2013/en/
*  WHO | Experts conclude that recommendations on pandemic influenza vaccines are still valid
Experts conclude that recommendations on pandemic influenza vaccines are still valid. Media centre News News releases Previous years. Experts conclude that recommendations on pandemic influenza vaccines are still valid Note for the media. Geneva - Previous recommendations on who should be vaccinated with the H1N1 pandemic influenza vaccine still stand according to the World Health Organization's WHO Strategic Advisory Group of Experts SAGE on Immunization, the principal advisory group to WHO for development of policy related to vaccines and immunization. Robust and independent oversight of new strategic plan on polio eradication needed SAGE recognized the substantial progress made in the last 12 months by national authorities in reducing transmission of wild poliovirus, particularly in northern Nigeria, northern India and many re-infected countries, but cautioned against excessive enthusiasm. "Recent progress suggests that interruption of transmission of poliovirus is now within our grasp," said Salisbury, "I...
http://who.int/mediacentre/news/notes/2010/sage_20100528/en/
*  Announcement: National Influenza Vaccination Week — December 8–14, 2013
. Announcement: National Influenza Vaccination Week December 8 14, 2013. Skip directly to search Skip directly to A to Z list Skip directly to site content CDC Home. CDC 24/7: Saving Lives. Protecting People. Search The CDC. Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov. Morbidity and Mortality Weekly Report MMWR. MMWR. Share Compartir. Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation in the subject line of e-mail. Announcement: National Influenza Vaccination Week December 8 14, 2013 The U.S. Department of Health and Human Services, CDC, state and local health departments, and other health agencies will observe National Influenza Vaccination Week December 8 14, 2013, with educational and promotional activities scheduled across th...
http://cdc.gov/mmwr/preview/mmwrhtml/mm6248a5.htm
*  H1N1 influenza virus vaccine (injectable) | Health Encyclopedia | Norris Cotton Cancer Center
H1N1 influenza virus vaccine injectable. Cancer Care. Cancer Care by Type of Cancer. Focus on Cancer Care. Preventing Cancer. Focus on Preventing Cancer. Breast Cancer. H1N1 influenza virus vaccine injectable. The injectable H1N1 influenza virus vaccine is a "killed virus" vaccine. The injectable form of H1N1 influenza virus vaccine is a "killed virus" vaccine and will not cause you to become ill with the flu virus that it contains. Keep track of any and all side effects you have after receiving this vaccine. If you ever have to receive another influenza virus vaccine in the future, you will need to tell the doctor if the first shot caused any side effects. H1N1 influenza virus vaccine is used to prevent infection caused by the pandemic 2009 H1N1 influenza virus. The injectable H1N1 influenza virus vaccine is a "killed virus" vaccine. What should I discuss with my healthcare provider before receiving this vaccine. Do not receive this vaccine if you have ever had an allergic reaction to a flu vaccine, or if yo...
http://cancer.dartmouth.edu/pf/health_encyclopedia/d07464a1
*  Safety of the Trivalent Inactivated Influenza Vaccine Among Children
... Article Safety of the Trivalent Inactivated Influenza Vaccine Among Children. Impact Factor: 5.73. ABSTRACT To our knowledge, there are no published population-based studies on the safety of the inactivated trivalent influenza vaccine among children. Significant plausible medically attended events identified in group 1 were then analyzed in group 2, using the same 2 control periods. Medically attended events significant in both groups were considered potentially associated with vaccination and were assessed by medical record review. This large screening safety study did not reveal any evidence of important medically attended events associated with pediatric influenza vaccination. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance. ABSTRACT: To evaluate and compare rates of febrile events, including febrile convulsion, following immunisation...
http://researchgate.net/publication/8200822_Safety_of_the_Trivalent_Inactivated_Influenza_Vaccine_Among_Children
*  High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older -
... Drugs.com MedNews. High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older. WASHINGTON, October 26, 2008 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that an investigational high-dose influenza vaccine demonstrated increased immune responses among adults 65 years of age and older compared with the standard influenza vaccine. The Phase III study of almost 4,000 people 65 years of age and older compared the high-dose influenza vaccine with the standard inactivated influenza vaccine formulated for the 2006-2007 season. The key finding is that the new high-dose vaccine increased the immune responses to all three influenza strains compared with standard vaccine in the study population. Statistically significant higher HAI titers against all three influenza virus strains were reported in those who received the high-dose vaccine compared with those who received the standard vaccine. Pre-defined criteria for ov...
http://drugs.com/clinical_trials/influenza-vaccine-shows-increased-immune-response-among-adults-65-years-age-older-5946.html
*  Did seasonal flu vaccination increase the risk of infection with pandemic H1N1 flu? -- ScienceDaily
Did seasonal flu vaccination increase the risk of infection with pandemic H1N1 flu. Did seasonal flu vaccination increase the risk of infection with pandemic H1N1 flu. Date: April 7, 2010 Source: Public Library of Science Summary: In September 2009, news stories reported that researchers in Canada had found an increased risk of pandemic H1N1 influenza in people who had previously been vaccinated against seasonal influenza. Did seasonal flu vaccination increase the risk of infection with pandemic H1N1 flu. In September 2009, news stories reported that researchers in Canada had found an increased risk of pandemic H1N1 pH1N1 influenza in people who had previously been vaccinated against seasonal influenza. This study confirmed that the seasonal vaccine provided protection against seasonal influenza, but found it to be associated with an increased risk of approximately 68% for pH1N1 disease. Does Seasonal Influenza Vaccination Increase the Risk of Illness with the2009 A/H1N1 Pandemic Virus. "Did seasonal flu vacc...
http://sciencedaily.com/releases/2010/04/100406172635.htm
*  CDC H1N1 Flu | H1N1 Clinicians General Questions and Answers
Will the 2009 H1N1 vaccine be recommended for patients who had influenza-like illness since spring 2009. In addition, people recommended for seasonal vaccine should get a seasonal vaccine because infection with the 2009 H1N1 virus does not provide protection against seasonal influenza viruses. Can seasonal influenza vaccine and 2009 H1N1 vaccine be given at the same visit. Both seasonal and 2009 H1N1 vaccines are available as inactivated and live attenuated LAIV formulations. Consequently, providers can administer seasonal and 2009 H1N1 inactivated vaccines, seasonal inactivated vaccine and 2009 H1N1 LAIV, or seasonal LAIV and inactivated 2009 H1N1 at the same visit, or at any time before or after each other. Live attenuated seasonal and live 2009 H1N1 vaccines should NOT be administered at the same visit until further studies are done. Live 2009 H1N1 vaccine can be administered at the same visit as any other live or inactivated vaccine EXCEPT seasonal live attenuated influenza vaccine. If seasonal live atten...
http://cdc.gov/H1N1flu/vaccination/clinicians_qa.htm
*  Effectiveness of Inactivated Influenza Vaccine for Preventio... : The Pediatric Infectious Diseas
... e Journal. The Pediatric Infectious Disease Journal Wolters Kluwer Health Logo. Effectiveness of Inactivated Influenza Vaccine for Preventio... A A You could be reading the full-text of this article now if you... If you have access to this article through your institution, you can view this article in. Effectiveness of Inactivated Influenza Vaccine for Prevention of Otitis Media in Children Ozgur, Senem Konuk MD*; Beyazova, Ufuk MD*; Kemaloglu, Yusuf Kemal MD†; Maral, Isil MD‡; Sahin, Figen MD*; Camurdan, Aysu Duyan MD*; Kizil, Yusuf MD†; Dinc, Erdem MD†; Tuzun, Hakan MD‡. Objective: The objective of this study was to evaluate the effectiveness of inactivated influenza vaccine in preventing acute otitis media AOM and otitis media with effusion OME in children aged 6 to 60 months who attend day care. Result: The frequencies of AOM, OME and total otitis media episodes in vaccinated children were 2.3%, 22.8% and 25.2%, respectively, and these frequencies were 5.2%, 31.1% and 36.3% in the unvaccinated group. ...
http://journals.lww.com/pidj/Abstract/2006/05000/Effectiveness_of_Inactivated_Influenza_Vaccine_for.5.aspx
*  State law and influenza vaccination of health care personnel - ResearchGate
... Article State law and influenza vaccination of health care personnel. Alexandra Stewart George Washington University Message author. George Washington University, School of Public Health and Health Services, Department of Health Policy, 2021 K St. Impact Factor: 3.62. This study analyzes laws in twenty states that address influenza vaccination requirements for HCP who practice in acute or long-term care facilities in the United States. Impact of hospital policies on health care workers' influenza vaccination rates. Methods: To compare hospitals that mandate annual health care worker HCW influenza vaccination with and without consequences for noncompliance, a 34-item survey was mailed to an infection control professional in 964 hospitals across the United States in 4 waves. The change in vaccination rates in hospitals with mandates with consequences 19.5% was nearly double that of the hospitals with mandates without consequences 11%; P=.002. Presence of a state law regulating HCW influenza vaccination...
http://researchgate.net/publication/233877897_State_law_and_influenza_vaccination_of_health_care_personnel
*  foodconsumer.org - Seasonal flu vaccine raises swine flu risk, vitamin D can help fight the virus
... Home. Nutrition. Avoiding Illness. Safety. Environment. Food Chemicals. Cooking Dining. Shopping. Sci-Tech. Politics. Opinion. Non-food. Watch-List. . Search. Home. Non-food. Miscellaneous. Seasonal flu vaccine raises swine flu risk, vitamin D can help fight the virus. Seasonal flu vaccine raises swine flu risk, vitamin D can help fight the virus. 04/07/2010 00:20:00 admin. The conventional seasonal flu vaccine may have increased risk of infection with 2009 pandemic H1N1 swine flu, according to Canadian researchers. Four studies suggest the same thing. In one study, the researchers analysed data from an ongoing sentinel monitoring system to compare people receiving seasonal flu vaccine with those who did not for their risk of H1N1 swine flu in 2009 and found that seasonal flu vaccine was associated with a 68 percent increased risk for getting infected with swine flu. Other three studies found that seasonal flu vaccination was linked to a 1.4 to 5.0 fold greater risk of getting swine flu. Danuta Skowronsk...
http://foodconsumer.org/newsite/mobile/Non-food/Miscellaneous/seasonal_flu_vaccine_raises_swine_flu_risk_0604100821.html
*  Eurosurveillance - Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 am
Eurosurveillance - Low and decreasing vaccine effectiveness against influenza A H3 in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study. Low and decreasing vaccine effectiveness against influenza A H3 in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study. Characteristics of A H3 influenza cases n=446 and test-negative controls n=587 in vaccination target groups, multicentre case–control study, seven European Union countries, week 46/2011–week 17/2012. Pooled crude and adjusted 2011/12 seasonal influenza vaccine effectiveness against laboratory-confirmed A H3 influenza in vaccination target groups, at study sites in seven European Union countries, week 46/2011–week 17/2012 patients with complete information, n=1,016. Pooled adjusted 2011/12 seasonal vaccine effectiveness against laboratory-confirmed influenza A H3 cases in vaccination target groups, by time since vaccination, at study sites in seven E...
http://eurosurveillance.org/ViewArticle.aspx?ArticleId=20390
*  Novavax Inc Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
... Post Jobs. Jobs. Search Life Sciences Jobs. Search News. Novavax, Inc. NVAX Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals Madrid: ROVI to develop Novavax's virus-like-particle VLP -based vaccines against influenza in the country of Spain. Novavax is free to seek a new partner for its pandemic and seasonal influenza vaccine development efforts in Europe in the future. About Novavax Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle VLP technology. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. Novavax, Inc. Related News Novavax, Inc. NVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus RSV ...
http://biospace.com/news_story.aspx?StoryID=170073&full=1
*  Efficacy and Immunologic Responses to Influenza Vaccine in H... : JAIDS Journal of Acquired Immun
... e Deficiency Syndromes. JAIDS Journal of Acquired Immune Deficiency Syndromes Wolters Kluwer Health Logo. Efficacy and Immunologic Responses to Influenza Vaccine in H... A A JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 June 2005 - Volume 39 - Issue 2 - pp 167-173 Clinical Science. Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-Infected Patients Yamanaka, Hikaru MD*†; Teruya, Katsuji MD*; Tanaka, Mari PhD*; Kikuchi, Yoshimi MD*; Takahashi, Takao MD†; Kimura, Satoshi MD*; Oka, Shinichi MD*; the HIV/Influenza Vaccine Study. Influenza vaccine is recommended for HIV-1-infected patients. In baseline antibody-negative patients, anti-H1 and anti-H3 antibody responses to the vaccination were significant in those patients with a CD4 count 200 cells/μL compared with those with a CD4 count 200 cells/μL P 0.05. Specific CD4 responses correlated with HIV-1 viral load VL , especially in patients treated with highly active antiretroviral therapy HAART compared with those without HAART P 0.01...
http://journals.lww.com/jaids/pages/articleviewer.aspx?year=2005&issue=06010&article=00007&type=abstract
*  Notice to Readers: Availability of Additional Trivalent Inactivated Influenza Vaccine for Adults
... Afluria. For assistance, please send e-mail to: mmwrq@cdc.gov. Notice to Readers: Availability of Additional Trivalent Inactivated Influenza Vaccine for Adults Afluria. On September 28, 2007, CSL Biotherapies, Inc., King of Prussia, Pennsylvania received approval from the Food and Drug Administration for use of Afluria, a trivalent inactivated influenza vaccine TIV administered intramuscularly in persons aged 18 years 1. Afluria can be used for any adult influenza vaccine indication 2. CDC estimates that manufacturers of the six vaccines will supply a record 132 million doses of influenza vaccine for the 2007--08 influenza season. Afluria is available in a 0.5 mL preservative-free, single-dose, prefilled syringe and in a 5 mL multidose vial containing 10 doses. Thimerosal, a mercury derivative, is added as a preservative to the multidose vial; each 0.5 mL dose contains 24.5 g of mercury. Additional information is available from the manufacturer's package insert 3 and CSL Biotherapies, Inc., telephone 888...
http://cdc.gov/mmwr/preview/mmwrhtml/mm5646a5.htm
*  POEMs: Influenza Vaccine Reduces Risk of Adverse Cardiovascular Events in High-Risk Patients - Ameri
... can Family Physician. Previous article Next article. Feb 1, 2014 Issue. POEMs Influenza Vaccine Reduces Risk of Adverse Cardiovascular Events in High-Risk Patients. FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access. FREE PREVIEW. Purchase online access to read the full version of this article. Clinical Question Does the influenza vaccine lower the risk of major adverse cardiovascular events in adults with coronary disease. Bottom Line This meta-analysis found that the influenza vaccine is associated with a significantly lower risk of major adverse cardiovascular events in adults with coronary disease. The benefit of influenza vaccination is strongest in adults with a history of recent acute coronary syndrome within the previous six months number needed to treat = 8. Six randomized controlled trials met inclusion criteria for the final meta-analysis. These trials N = 6,735 compared influenza vaccine with placebo or control for a mean duration of ...
http://aafp.org/afp/2014/0201/p224a.html
*  11 Things for Parents to Know About the 2015-2016 Flu Vaccine - HealthyChildren.org
... Safety Prevention. Safety Prevention. Safety & Prevention. Healthy Children > Safety & Prevention > Immunizations > 11 Things for Parents to Know About the 2015-2016 Flu Vaccine Safety & Prevention. 11 Things for Parents to Know About the 2015-2016 Flu Vaccine. Article Body ​ By: Kathleen Berchelmann M.D., FAAP It's time to get flu shots for your family before your house is full of fevers and dripping noses. 2015-2016 influenza vaccine : 1. The American Academy of Pediatrics AAP and the Center for Disease Control and Prevention CDC strongly recommends annual influenza immunization for all people ages 6 months and older, including children and adolescents. Call your pediatrician to ask when the vaccine will be available. The quadrivalent live attenuated influenza vaccine LAIV4 is given by intranasal spray and is approved for healthy patients 2 through 49 years of age. The quadrivalent influenza vaccines for the 2015-2016 season contain the same three strains as the trivalent vaccine, plus an additiona...
https://healthychildren.org/English/safety-prevention/immunizations/Pages/Prepare-Your-Family-for-Flu-Season.aspx
*  Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in re
... nal transplant recipients - ResearchGate. Article Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients. Non-adjuvanted and the adjuvanted influenza A H1N1/09 monovalent vaccine were recommended as a single dose to persons at risk including renal transplant recipients RTR. We analyzed the safety and the immune response of 2 influenza A H1N1/09 monovalent vaccines in RTR, and identified factors influencing the immune response. Methods: A total of 78 RTR received a single dose of either influenza A H1N1 2009 monovalent AS03-adjuvanted vaccine or a non-adjuvanted vaccine, and 58 healthy controls received a single dose of non-adjuvanted vaccine. Results: Among RTR, after adjuvanted and non-adjuvanted H1N1 vaccination, the SP rate increased from 16.7% to 61.7% P 0.001 and to 50% P 0.001, and SC rates were 61.7% and 50%, respectively. Pre-vaccination GMT for the adjuvanted and non-adjuvanted RTR vaccine groups and healthy controls was 9.7 9...
http://researchgate.net/publication/230654454_Antibody_response_to_the_non-adjuvanted_and_adjuvanted_influenza_A_H1N109_monovalent_vaccines_in_renal_transplant_recipients
*  Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncer
... tainty. College of Veterinary Medicine. Oregon State University. Search for people and pages. College of Veterinary Medicine. College of Veterinary Medicine Select to search All of OSU Select to search for People Select to search for Media. College of Veterinary Medicine. Graduate Programs Request information Contacts, Map, and Directions. Curriculum Summer Research Programs Morris Animal Foundation Training Opportunities Dean s Office Contacts Vet Gazette Blog McDowell Veterinary Library. About Us Veterinary Databases Library Services. Canine Cancer Clinical Trials Pet Memorial Program Tours OSU Summer Veterinary Experience Contacts, Map, and Directions. Faculty Staff. Library Resources Vet Gazette Blog. Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty. Title Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty. Journal Vaccine. Here we used a mathematical model parametrized with survey-based c...
http://vetmed.oregonstate.edu/publications/optimal-targeting-seasonal-influenza-vaccination-toward-younger-ages-robust-parameter-u
*  AOL.com Search Video - Cold Flu Vaccines
... Back to Mobile View. 0 nb cid nb clickOther -tt-nb this.style.behavior='url #default#homepage ';this.setHomePage 'http://www.aol.com/?mtmhp=optinnewaol network-banner-promo mtmhpBanner. X. 14. http://portal.aolcdn.com/p5/forms/26319/4480a515-748d-418d-870e-064d5af6be66.png. AOL.com Search Video - Cold Flu Vaccines. Sign In. Sign Up. My Account. Set AOL as Homepage. AOL Mail. News. Sports. Entertainment. Lifestyle. Finance. Weather. Videos. Set Location. Weather. Weather. 300. Change Location. SearchResults. Videos: Find a video. cold flu vaccines|12|1 1 - 12 out of 4671 results. 2015-2016 Flu Vaccines Now Available 01:20 2015-2016 flu vaccines now available Date: September 09, 2015 Source: RTV6 The Indy Channel. A Universal Flu Vaccine Just Got More Plau... 04:39 We are now one step closer to a universal flu vaccine. Date: September 01, 2015 Source: HuffPost Live Highlights. Should You Get a Flu Vaccine. 02:40 Is the flu vaccine really effective, or a major cash injection for the pharmaceutical industry....
http://aol.com/search/video/?q=cold flu vaccines&tag=true
*  Protective properties of influenza vaccines revealed -- ScienceDaily
... Protective properties of influenza vaccines revealed. The study led by Octavio Ramilo, MD, chief of Infectious Diseases and an investigator in the Center for Vaccines and Immunity at Nationwide Children's Hospital and professor of Pediatrics at The Ohio State University OSU College of Medicine, and Hideki Ueno, MD, PhD, an investigator at the Baylor Institute for Immunology Research at Baylor University, demonstrates how certain T cells in the blood are stimulated to provide protective antibody responses with seasonal flu vaccines. "Given that seasonal influenza vaccines induce antibody responses mainly through boosting the recall response of the immune system, this lack of correlation might reflect the lack of H1N1 specific immunity in some children," explains study co-author Emilio Flano, PhD, a principal investigator in the Center for Vaccines and Immunity at Nationwide Children's and an associate professor of Pediatrics at OSU College of Medicine. Nationwide Children's Hospital. "Protective propertie...
http://sciencedaily.com/releases/2013/03/130322154024.htm
*  CDC - Media Relations - MMWR - March 4, 2005
... Update: Influenza Activity United States 2004-05. Interventions to Increase Influenza Vaccination of Health-Care Workers California and Minnesota. Vaccination Coverage Among Callers to a State Influenza Hotline Connecticut, 2004-05 Influenza Season. Update: Influenza Activity United States 2004-05 Influenza season in the United States is not over; influenza activity has not yet clearly peaked. The viruses circulating this year include both influenza A and B viruses, but influenza A viruses have predominated and most of those that have been sub-typed have been influenza A H3N2 viruses. Interventions to Increase Influenza Vaccination of Health-Care Workers California and Minnesota Many more health care workers can be vaccinated if health care facilities combine education of employees with efforts to make the vaccination convenient and available without cost. However, influenza vaccination rates among HCWs in the United States remain low. Vaccination Coverage Among Callers to a State Influenza Hotline Conne...
http://cdc.gov/media/mmwrnews/2005/n050304.htm
*  influenza virus vaccine (injection) | UW
UW Health. Skip to Content UW Health SMPH. American Family Children's Hospital Home. Bill Pay. Classes and Support Groups. Prescription Refill. Services. Clinics Hospitals. Search. The injectable influenza virus vaccine flu shot is a "killed virus" vaccine. Becoming infected with influenza is much more dangerous to your health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is extremely low. What is influenza virus vaccine. Influenza virus vaccine is used to prevent infection caused by influenza virus. The injectable influenza virus vaccine flu shot is a "killed virus" vaccine. Influenza virus vaccine is for use in adults and children who are at least 6 months old. Becoming infected with influenza is much more dangerous to your health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is extremely low. Like any vaccine, influenza virus vaccine may not...
http://uwhealth.org/health/topic/multum/fluzone-intradermal-20112012/d01164a1.html
*  influenza virus vaccine (injection) | UW
UW Health. Skip to Content UW Health SMPH. American Family Children's Hospital Home. Bill Pay. Classes and Support Groups. Prescription Refill. Services. Clinics Hospitals. Search. The injectable influenza virus vaccine flu shot is a "killed virus" vaccine. Becoming infected with influenza is much more dangerous to your health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is extremely low. What is influenza virus vaccine. Influenza virus vaccine is used to prevent infection caused by influenza virus. The injectable influenza virus vaccine flu shot is a "killed virus" vaccine. Influenza virus vaccine is for use in adults and children who are at least 6 months old. Becoming infected with influenza is much more dangerous to your health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is extremely low. Like any vaccine, influenza virus vaccine may not...
http://uwhealth.org/health/topic/multum/fluzone-preservative-free-2012-2013/d01164a1.html
*  IAC Express Issue 895
Immunization Action Coalition. Questions and Answers What's New: Handouts. Bulk quantities of the 2010-11 influenza vaccine pocket guides are available--FREE!--from the National Influenza Vaccine Summit. Here's a roundup of current influenza vaccination news from the National Influenza Vaccine Summit. 1 Bulk quantities of the 2010-11 influenza vaccine pocket guides are available--FREE!--from the National Influenza Vaccine Summit. To aid in efforts to vaccinate against influenza, the Immunization Action Coalition is inviting IAC Express readers to place orders now for bulk quantities of the National Influenza Vaccine Summit's 2010-11 Seasonal Influenza Vaccination Pocket Information Guides. If you have questions, email admininfo@immunize.org BACKGROUND These pocket guides were developed by, and are being provided under the sponsorship of the National Influenza Vaccine Summit, http://www.preventinfluenza.org The Summit brings together public and private stakeholders to facilitate and promote influenza vaccinati...
http://immunize.org/express/issue895.asp
*  A shot in the dark? Some say flu vaccine hard to find | The News-Messenger | thenews-messenger.com
A shot in the dark. Some say flu vaccine hard to find. The News-Messenger. thenews-messenger.com. SHOPPING. News. USA Today. Search Search in News Archives Local Deals Yellow Pages. A shot in the dark. Some say flu vaccine hard to find. A A An increased demand for the flu vaccine has led to spot shortages. USA Today news. USA Today nation. Some parts of the country are experiencing spot shortages of flu vaccine because of increased demand in a flu season that started earlier and is more severe than previous years. flu vaccine manufacturers have increased the number of doses they expect to produce this year to 145 million from previous estimates of 137 million, Skinner said. "We had 112 million people vaccinated by the end of November." The CDC is working with the National Influenza Vaccine Summit, a coalition that monitors the flu and vaccine supply, to tell doctors and other health care providers which distributors and vaccine manufacturers have vaccine available to order, Skinner said. It's more an effect o...
http://archive.thenews-messenger.com/usatoday/article/1839825?odyssey=mod_sectionstories&from=global
*  CDC Advises Broadening of Influenza's Vaccination Efforts
CDC Advises Broadening of Influenza's Vaccination Efforts. Healthcare. India Healthcare. USA. World Healthcare. Medical News. USA Channel. subscribe to USA newsletter. Healthcare : USA. CDC Advises Broadening of Influenza's Vaccination Efforts. “It is always a priority for us to want to reach people who are at the highest risk of complications from influenza and get them vaccinated,” said CDC Director Dr. “Those efforts should continue, but we also recognize that many health care providers have enough vaccine to expand their efforts, and overall, more vaccine is becoming available weekly.”. By Centers for Disease Control and Prevention CDC, USA, The Centers for Disease Control and Prevention CDC today said that the supply of vaccine for this flu season is good and it is time to broaden vaccinations beyond the high-risk groups. The CDC advised that flu shot providers who have sufficient supplies of vaccine should broaden their vaccination efforts to include other people, especially 50-to-64 year olds, who ...
http://rxpgnews.com/usahealthcare/CDC_Advises_Broadening_of_Influenza_s_Vaccination__2734_2734.shtml
*  Auto-immunity in Lupus Patients After Influenza Vaccine - Full Text View - ClinicalTrials.gov
... Auto-immunity in Lupus Patients After Influenza Vaccine GRIPLUP This study has been completed. Sponsor: Assistance Publique - H pitaux de Paris Collaborator: Institut National de la Sant Et de la Recherche M dicale, France Information provided by: Assistance Publique - H pitaux de Paris. ClinicalTrials.gov Identifier: NCT01072734 First received: February 19, 2010 Last updated: October 11, 2010 Last verified: October 2010 History of Changes. Annual influenza vaccination is recommended in patients with systemic lupus erythematosus SLE. Systemic Lupus Erythematosus SLE. Further study details as provided by Assistance Publique - H pitaux de Paris:. For that purpose, we will assay in lupus patients the cellular level of CXCR4 before and after administration of influenza vaccine and correlate the expression levels of CXCR4 with: 1 the evolution of clinical and biological signs of autoimmunity and 2 the humoral immune response towards influenza. If influenza vaccine has not been associated so far with increased...
https://clinicaltrials.gov/ct2/show/NCT01072734
*  IAC EXPRESS - Issue #485
Aventis Pasteur ships more than 2 million doses of influenza vaccine to providers who serve high-priority groups. Last week CDC announced priority groups for vaccination with inactivated influenza vaccine for the 2004-2005 influenza season:. 4 of 7 October 18, 2004 AVENTIS PASTEUR SHIPS MORE THAN 2 MILLION DOSES OF INFLUENZA VACCINE TO PROVIDERS WHO SERVE HIGH-PRIORITY GROUPS On October 15, CDC issued a press release announcing that it and Aventis Pasteur collaborated to ship more than 2 million doses of influenza vaccine to providers who serve high-priority groups. ********************** For Immediate Release October 15, 2004 CDC/AVENTIS PASTEUR COLLABORATE TO SHIP MORE THAN 2 MILLION DOSES OF INFLUENZA VACCINE TO PROVIDERS WHO SERVE HIGH-PRIORITY GROUPS More than 2 million doses of influenza vaccine were shipped this week by Aventis Pasteur to health care providers throughout the country who serve the high-priority groups recommended by the Centers for Disease Control and Prevention to receive influenza vac...
http://immunize.org/genr.d/issue485.htm
*  Influenza research
Current vaccine research is focussed on clade 1 viruses, but the clade 2 virus is antigenically distinct and a clade 1 vaccine will probably not protect against a pandemic caused by clade 2 virus. In May 2006, the United States Department of Health and Human Services awarded Novartis a $220 million contract to develop cell-based flu vaccines, and Novartis has said the money would go toward the cost of the new facility. :Vaccine production capacity: The protective immune response generated by current influenza vaccines is largely based on viral hemagglutinin HA and neuraminidase NA antigen s in the vaccine. In addition to supporting basic research on cell-based influenza vaccine development, HHS is currently supporting a number of vaccine manufacturers in the advanced development of cell-based influenza vaccines with the goal of developing U.S.-licensed cell-based influenza vaccines produced in the United States. Cell culture cell-based manufacturing technology can be applied to influenza vaccines as they are ...
https://en.wikipedia.org/wiki/Influenza_research
*  Philadelphia Immunization Program | Flu Vaccine Campaign
The Philadelphia Immunization Program coordinates a citywide Community-based Influenza Vaccine Campaign for adults each year starting in October. The program vaccinates adults aged 19 through 64 years who do not have health insurance and have no alternative source for medical care, or who are unable to access their usual source of care. The community-based flu vaccine clinics are open to uninsured Philadelphia adults meeting the current recommendations for influenza vaccination as defined by the Advisory Committee on Immunization Practices ACIP. Adults 19 through 64 years of age who are uninsured adults mandated by the CDC Adults 65 and older cannot be administered PDPH flu vaccine through this program. For adults who have health insurance, the Philadelphia Immunization Program encourages patients to seek immunizations from their regular source of medical care. What is the Community-based Flu Vaccine Campaign. Each year the program coordinates a citywide community-based seasonal influenza vaccination campaign...
http://kids.phila.gov/index.php/programs/influenza/
*  FDA approves four-strain Sanofi influenza vaccine | GlobalPost
FDA approves four-strain Sanofi influenza vaccine. Jun 10, 2013 @ 3:39 AM Published. FDA approves four-strain Sanofi influenza vaccine. By Ransdell Pierson. Reuters - French drugmaker Sanofi SA said the U.S. Food and Drug Administration had approved its four-strain influenza vaccine, which is meant to provide better protection from infection than traditional three-strain flu vaccines. The Fluzone Quadrivalent vaccine is licensed for adults, adolescents and children 6 months and older, and will be available in the upcoming 2013-2014 flu season, the company said on Monday. The 2013 influenza season will be the first when quadrivalent influenza vaccines will be available in the United States. marketing approval for the first four-strain seasonal flu vaccine, called Fluarix Quadrivalent. The injectable vaccine, approved to immunize adults and children age 3 and older against flu virus subtypes A and B, is also slated for introduction in the 2013-14 flu season. Three-strain flu vaccines are currently administered ...
http://globalpost.com/dispatch/news/thomson-reuters/130610/fda-approves-four-strain-sanofi-influenza-vaccine
*  Supply of Flu Vaccines, Medicines Will Keep People Safe
... For Immediate Release Department of Health and Human Services October 19, 2004. Supply of Flu Vaccines, Medicines Will Keep People Safe. The Flu Vaccine Discussed with HHS Secretary Tommy Thompson. HHS Says Supply of Flu Vaccines, Medicines Will Help Keep People Safe During Coming Flu Season Department Stockpiles Medicine, Coordinates Flu Response, Invests in New Technology. HHS Secretary Tommy G. Thompson said today that about 60 million doses of influenza vaccine combined with an ample supply of antiviral medicines -- potentially enough for more than 40 million people during the flu season -- puts America in a strong position to keep people safe during the upcoming flu season. Secretary Thompson said the nation's cache of vaccine and medicines includes an additional 2.6 million doses of influenza vaccine that Aventis said today it will make available in January. The Centers for Disease Control and Prevention CDC also issued today interim guidance on the use of antiviral medicines for preventing and tre...
http://georgewbush-whitehouse.archives.gov/news/releases/2004/10/print/20041019-DHHS.html
*  A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA - Full T
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine CSL425 in Healthy Adults in the USA - Full Text View - ClinicalTrials.gov. Other Sites About Clinical Studies. About This Site. A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine CSL425 in Healthy Adults in the USA This study has been completed. ClinicalTrials.gov Identifier: NCT00958126 First received: August 12, 2009 Last updated: August 31, 2012 Last verified: August 2012 History of Changes. Study Results. Biological: CSL425 Biological: Placebo. Further study details as provided by CSL Limited:. Primary Outcome Measures: Seroconversion Rate 21 Days After the First Vaccination Seroconversion rate: the proportion of participants achieving seroconversion in hemagglutination inhibition HI antibody titer. Seroconversion is defined as participants with a baseline titer of less than 1:10 achieving a post-vaccination HI antibody titer of 1:40 or more; or participants with a baseline HI titer of 1:10 or more achieving a four-fold or greater increase in post-v...
https://clinicaltrials.gov/ct2/show/NCT00958126?intr=Thimerosal&rank=17
*  Identifying Children With Chronic Conditions for Influenza Vaccination Using a Statewide Immunizatio
... n Registry: Initial Experiences of Primary Care Providers - ResearchGate. Article Identifying Children With Chronic Conditions for Influenza Vaccination Using a Statewide Immunization Registry: Initial Experiences of Primary Care Providers. Impact Factor: 1.47. ABSTRACT Children with chronic medical conditions are at increased risk of complications from influenza, yet their vaccination rates are low. The Michigan Care Improvement Registry MCIR, a statewide immunization registry, was expanded in 2006 to include an indicator, based on Medicaid administrative claims, that prompts providers to offer influenza vaccine to high-risk children ie, those with chronic conditions. To assess primary care providers' experiences with the MCIR high-risk indicator. DOI:10.1097/PHH.0b013e318250b064 1.47 Impact Factor. Statewide Pandemic Influenza Vaccination Reminders for Children with Chronic Conditions. ABSTRACT: Objectives: We evaluated the use of a statewide immunization information system IIS to target influenza vacci...
http://researchgate.net/publication/223985614_Identifying_Children_With_Chronic_Conditions_for_Influenza_Vaccination_Using_a_Statewide_Immunization_Registry_Initial_Experiences_of_Primary_Care_Providers
*  H1N1 (swine) Influenza Vaccine - News, Information on H1N1 (swine) Influenza Vaccine - NY Times Heal
H1N1 swine Influenza Vaccine - News, Information on H1N1 swine Influenza Vaccine - NY Times Health Information. Log In Register Now Help. Home Page Today's Paper Video Most Popular Times Topics. Search All NYTimes.com. Health Guide. World U.S. N.Y. / Region Business Technology Science. Health Research Fitness Nutrition Money Policy Views Health Guide. Sports Opinion Arts Style Travel Jobs Real Estate Autos. Search Health 3,000+ Topics. Send Feedback. Health. Times Health Guide. h. H1N1 swine Influenza Vaccine. News & Features. H1N1 swine Influenza Vaccine. Overview News & Features. Multimedia. Video. Students Get Swine Flu Vaccine. Video. Vaccine Shortfall. Slide Show. The School Nurse. Video. Critics' Picks: 'Safe'. Video. Watch Out, Swine Flu. Video. Will Half The Country Get Swine Flu. Video. Swine Flu Precautions. Slide Show. Protecting the Pigs. Video. W.H.O. Calls Outbreak a Flu Pandemic. Slide Show. Living Among Trash. Related Topics. H1N1 Swine Influenza Pneumonia - Adults Community Acquired Acute Res...
http://nytimes.com/health/guides/specialtopic/h1n1-swine-influenza-vaccine/news-and-features.html
*  Search of: vaccination - List Results - ClinicalTrials.gov
Condition. Rank Status Study 1 Completed Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine. Interventions: Biological: Vaccination with Fluval P and Fluval AB influenza vaccines; Biological: Vaccination with Fluval P monovalent influenza vaccine. Interventions: Other: arm 1: DC Vaccine + RT; Other: arm 2: DC Vaccine + IFN-alfa; Other: arm 3: both arm 1 and 2 + RT; Biological: arm 4: DC Vaccine. Interventions: Biological: Fluzone vaccine with JVRS-100 adjuvant; Biological: Fluzone vaccine. 4 Completed Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children. Interventions: Biological: Vaccination with Fluval P monovalent influenza vaccine; Biological: Vaccination with Fluval AB; Biological: Vaccination with Fluval AB Novo. Interventions: Biological: DC Vaccine Cyclophosphamide; Biological: DC Vaccine Placebo. Interventions: Biological: DC Vaccine + IFN; Biological: AdVTMM2/DC Vaccination. Interventions: Biological: Immunization Schedule patients 7 years.; Biolog...
https://clinicaltrials.gov/ct2/results?intr=vaccination&show_rss=Y&sel_rss=new14
*  IAC Express Issue 838
The National Influenza Vaccine Summit website: http://www.preventinfluenza.org IAC's Seasonal Influenza web section: http://www.immunize.org/influenza IAC's H1N1 Influenza web section: http://www.immunize.org/h1n1 CDC's Seasonal Flu web section: http://www.cdc.gov/flu CDC's Novel H1N1 Flu web section: http://www.cdc.gov/h1n1flu To access IAC's print pieces related to influenza, go to: http://www.immunize.org/printmaterials/dis inf.asp. VISs FOR THE INJECTABLE 2009 H1N1 INFLUENZA VACCINE To access the new translations Hindi, Karen, Kurdish, Laotian, Marshallese, Nepali, and Swahili, of the VIS for the injectable 2009 H1N1 influenza vaccine, as well as this VIS in English and other translations, go to: http://www.immunize.org/vis/vis h1n1 inactive.asp Click on the pertinent languages. VISs FOR THE NASAL-SPRAY 2009 H1N1 INFLUENZA VACCINE To access the new translations Hindi, Karen, Kurdish, Laotian, Marshallese, Nepali, and Swahili, of the VIS for the nasal-spray 2009 H1N1 influenza vaccine, as well as this VIS ...
https://immunize.org/express/issue838.asp
*  Better flu vaccination for moms-to-be - UPI.com
... About Us. UPI en Español. Log in or Register. Top News. U.S. News. World News. Entertainment. Movies. Music. TV. Odd News. The Almanac. Business. Security Industry. Energy Industry. Sports. Science. Health. Analysis. Photos. Latest Photos. News. Entertainment. Sports. Features. Archives. Archive. . Home / Health News Better flu vaccination for moms-to-be. Feb. 23, 2012 at 10:17 PM Follow @upi. Comments. ATLANTA, Feb. 23 UPI -- Pregnant women who were offered or recommended a seasonal flu vaccination by their doctor were more likely to become immunized, U.S. health officials said. The American College of Obstetricians and Gynecologists and the Advisory Committee on Immunization Practices recommend influenza vaccination for women who will be pregnant during the influenza season, regardless of trimester. A report published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report said pregnant women were at increased risk during the 2009/2010 influenza season for severe disea...
http://upi.com/Health_News/2012/02/23/Better-flu-vaccination-for-moms-to-be/UPI-65741330053443/?rel=26591333139665
*  Wistar Institute researchers exploring a universal influenza vaccine that would eliminate annual flu
... shots - Drug Store News. Pharmacy news and CE. DSN DrugStoreNews.  Latest News opener. Retail. Products. Top Retailers opener. Kroger. Pharmacy opener. Retail Clinics. Insights opener. Special Reports. Promo Watch. Magazine opener. Subscribe. Advertise. Show Watch. Advertise. Wistar Institute researchers exploring a universal influenza vaccine that would eliminate annual flu shots. PHILADELPHIA A team of scientists at The Wistar Institute has determined that it might be possible to stimulate the immune system against multiple strains of influenza virus by sequentially vaccinating individuals with distinct influenza strains isolated over the last century, researchers announced Monday. According to the Wistar researchers, their analysis could lead to an alternative approach to creating a universal flu vaccine a vaccine that would provide resistance to seasonal and pandemic influenza strains over many years, negating the need for an annual flu shot. Join our Facebook group to get all the latest news dedica...
http://drugstorenews.com/article/wistar-institute-researchers-exploring-universal-influenza-vaccine-would-eliminate-annual-fl?ad=studies-and-surveys
*  IHB - Questions & Answers
Can live vaccines and the influenza vaccine be administered on the same day. What side effects can I expect when I receive the injectable influenza vaccine. Live Attenuated Intranasal Vaccine LAIV, Intranasal Who should receive the live, attenuated intranasal vaccine. Pregnant women may receive the inactivated injectable influenza vaccine, during any point of gestation and postpartum; breastfeeding women may receive the inactivated or live vaccine. According to the ACIP and the American Academy of Pediatrics AAP : Children aged 6 months to 8 years who are receiving the influenza vaccine for the first time or whose previous vaccination status is unknown should receive two 2 doses of vaccine separated by at least four weeks. IIV can be used when vaccinating children aged 6 months to 8 years and LAIV FluMist for children aged 2 years and older, who have not been previously vaccinated. Can live vaccines and the influenza vaccine be administered on the same day. The inactivated injectable influenza vaccine may be ...
https://vaccines.mil/Questions_and_Answers/Disease/Influenza_-_Seasonal/The_Vaccines
*  IHB - Questions & Answers
Can live vaccines and the influenza vaccine be administered on the same day. What side effects can I expect when I receive the injectable influenza vaccine. Live Attenuated Intranasal Vaccine LAIV, Intranasal Who should receive the live, attenuated intranasal vaccine. Pregnant women may receive the inactivated injectable influenza vaccine, during any point of gestation and postpartum; breastfeeding women may receive the inactivated or live vaccine. According to the ACIP and the American Academy of Pediatrics AAP : Children aged 6 months to 8 years who are receiving the influenza vaccine for the first time or whose previous vaccination status is unknown should receive two 2 doses of vaccine separated by at least four weeks. IIV can be used when vaccinating children aged 6 months to 8 years and LAIV FluMist for children aged 2 years and older, who have not been previously vaccinated. Can live vaccines and the influenza vaccine be administered on the same day. The inactivated injectable influenza vaccine may be ...
https://vaccines.mil/Questions_and_Answers/Disease/Influenza_-_Seasonal/The_Vaccines/Live_Attenuated_Intranasal_Vaccine_(LAIV),_Intranasal_FluMistandreg;
*  Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year o
... f Age and Older - Full Text View - ClinicalTrials.gov. Other Sites About Clinical Studies. Glossary of Common Site Terms. About This Site. Linking to This Site. Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older This study has been completed. Biological: GSK Bio's influenza vaccine GSK2186877A Biological: Fluarix TM. Biological: GSK Bio's influenza vaccine GSK2186877A IM administration, two times one annual dose, 3 different lots will be tested. Because evaluation of data from this site did not reveal irregularities when compared with overall study data and because GSK has no current plans to use the data from the study in support of any regulatory filings, they were not excluded from the analyses reflected in this results summary. Previous vaccination in the last three years with an investigational adjuvanted candidate seasonal or pandemic influenza vaccine. Use of any investigational or non-registered product drug or vaccine other than the...
https://clinicaltrials.gov/ct2/show/study/NCT00753272?show_locs=Y
*  Influenza vaccine
 Influenza vaccine. Memorial Healthcare System. About Memorial Healthcare System. Influenza vaccine Definition An influenza vaccine protects you against the flu. Alternative Names Vaccine - influenza; Immunization - influenza; Flu shot; Flu vaccine Information The flu is a contagious respiratory disease caused by an influenza virus. There is also a high-dose version of the flu shot approved for people 65 and older. WHO SHOULD GET THE VACCINE The Centers for Disease Control and Prevention CDC recommend that everyone 6 months and older should receive the flu vaccine. The CDC recommends extra efforts to vaccinate the following people: Pregnant women or women who will be pregnant during the flu season Children younger than 5 years and especially those under 2 years but 6 months or older Household contacts and caregivers of children under the age of 6 months, including breastfeeding women Health care workers or those who live with a health care worker People who have chronic lung or heart disease People who have ...
http://mhs.net/library/HIE Multimedia/1/002025.html
*  Vaccination & Immunization Board Index: Phrases Starting with "F"
41 false positive on hepatitis b 34 false positive on hepatitis test 18 false positive test for hepatitis b 34 false positive test for hepatitis b 34 false positive test hepatitis b 42 false positives with hepatitis b 20 false testing for hepatitis b 17 feeling after tetanus shot 17 feeling spaced out after the flu 30 fever + 4 months shots 143 fever after 4 month shots 55 fever baby 4 month shots 25 finger tetanus 21 first place to get chicken pox 28 flu 7 months baby 255 flu and arm hurting 40 flu and arm hurting 40 flu injection 327 flu injection headache 13 flu injection headaches 15 flu injection pain 84 flu injection problems 67 flu injection reaction 46 flu injection reactions 80 flu injection side effects 120 flu injection site reactions 38 flu injections 279 flu injections reactions 27 flu like symptoms though had flu shot 58 flu shot and babies 61 flu shot and baby 147 flu shot and mono 24 flu shot and twice a year 53 flu shot arm hurts 14 flu shot babies 63 flu shot baby 160 flu shot during pregnan...
http://index.healthboards.com/vaccination/index/F/
*  Intercom - Upcoming Flu Vaccination Clinics
... Campus Life. News Events. Ithaca College Apply Now. Intercom. intercom home. about intercom. rss Search Intercom. Current Ithaca College community members may contribute stories and comments as well as view additional topics by logging in. Netpass password:. News for Faculty. News for Students. Archive. Faculty Council. Staff Council. roundup. E-mail Roundup. Sign up to receive a summary of Intercom headlines via e-mail three times a week. Upcoming Flu Vaccination Clinics Contributed by Lynn Porter on 10/06/2013 Email. Flu Vaccinations Dates Fall Semester 2013. Flu Vaccination Clinics:. Monday, October 14, 2013 Location: Office of Public Safety 2pm to 4pm. Tuesday, October 15, 2013 Location: Hammond Health Center 1pm to 4pm for students. Thursday, October 17 and Friday, October 18 Fall Break Location: Hammond Health Center 10am to 4pm. Tuesday, November 5, 2013 Benefits Fair Location: Emerson Suites 10am to 3pm. If a student would like to receive a flu vaccination, please contact the Hammond Health Cente...
http://ithaca.edu/intercom/article.php?story=2013100315001687
*  Supporting Influenza Vaccine Production in Vietnam - PATH Vaccine Resource Library
PATH | VRL Home Resources Topics About Follow: Twitter | RSS Vaccine Resource Library Home Resources Topics About Search Supporting Influenza Vaccine Production in Vietnam This fact sheet describes a project that PATH is implementing in collaboration with the Biomedical Advanced Research and Development Authority within the US Department of Health and Human Services. The project is supporting the enhancement of sustainable influenza vaccine production in Vietnam. PATH is collaborating with various groups in Vietnam to facilitate the production and clinical evaluation of safe and effective influenza vaccines and synergizing activities with work already under way in Vietnam through the World Health Organization. Author: PATH Published: 2015 » Download file (English) 111 KB PDF Resource types: PATH resource, Fact sheet Diseases/vaccines: Influenza Topics: Disease/vaccine specific information Regions: Asia Follow the VRL Follow us on Twitter Subscribe to our RSS feed Free access to journal articles for users in t...
http://path.org/vaccineresources/details.php?i=1004
*  .. Tag Archives: flu season .. Get your flu shot for free during SMU’s Fall 2015 clinics .. SMU
Tag Archives: flu season. ← Older posts. Get your flu shot for free during SMU’s Fall 2015 clinics. Posted on. October 2, 2015 by. Kathleen Tibbetts. The SMU Health Center has scheduled several free flu shot clinics for October and November 2015, with the first session set for Monday, Oct. 5 in the lobby of Dedman Center for Lifetime Sports. Clinics will take place at various places around the main campus, … Continue reading →. Posted in News, Save the Date. Tagged benefits, flu, flu season, flu shot clinics, flu shots, H1N1 flu, Health Center, preparedness, public health, swine flu. Comments Off on Get your flu shot for free during SMU’s Fall 2015 clinics. SMU urges flu shots and other preventive measures. Posted on. January 26, 2015 by. Kathleen Tibbetts. SMU health officials remind students, faculty and staff to take precautions against the flu and help prevent its spread by getting a flu shot. Potentially severe flu season According to the U.S. Centers for Disease Control, cases of influenza are exp...
http://blog.smu.edu/forum/tag/flu-season/
*  The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enter
PATH | VRL Home Resources Topics About Follow: Twitter | RSS Vaccine Resource Library Home Resources Topics About Search The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future This report provides a review of all aspects of influenza vaccine research and development, financing, manufacturing, efficacy, safety, regulatory issues, procurement, distribution, usage, public education, consumer acceptance, and public policy. The authors identify ten key findings and six high-level recommendations that they believe are essential to moving the international influenza vaccine enterprise toward critically needed novel-antigen, game-changing vaccines. Author: Center for Infectious Disease Research & Policy Published: 2012 » Download file (English) 3 MB PDF (Located at www.cidrap.umn.edu) Resource types: Report Diseases/vaccines: Influenza Topics: Advocacy and communications, Introduction and service delivery, Vaccine safe...
http://path.org/vaccineresources/details.php?i=1554
*  Reminder: RAF/Jeffco Onsite/Walk-in Flu Vaccination Clinic Today (10/24/13) | UCAR - University Corp
Reminder: RAF/Jeffco Onsite/Walk-in Flu Vaccination Clinic Today 10/24/13. UCAR - University Corporation for Atmospheric Research. Skip to main content. UCAR Home About Us. Jobs Study+Visit Opportunities Our Organizational Structure Locations+Contacts News. For News Media News Archive Events. Research+Resources Education. Resources for Educators Resources for Students Career Tips for Students+Mentors Background on Weather+Climate For Staff. Staff Notes Daily Staff News Committees+Assemblies Resources for Staff Closures+Emergencies. UCAR - University Corporation for Atmospheric Research. View the results at Google, or enable JavaScript to view them here. Home Committees Resources Staff News. You are here Home » Reminder: RAF/Jeffco Onsite/Walk-in Flu Vaccination Clinic Today 10/24/13. Planned one-day closure - NCAR Mesa Lab - 10/10/15. more info. Reminder: RAF/Jeffco Onsite/Walk-in Flu Vaccination Clinic Today 10/24/13. Sponsored by UCAR's Wellness Advisory Committee WAC, this event is open to UCAR employees, ...
https://www2.ucar.edu/for-staff/daily/announcements/2013-10-24/reminder-rafjeffco-onsitewalk-flu-vaccination-clinic-today
*  Seasonal Flu Q and A
Seasonal Flu Vaccine for Children. Seasonal Flu Vaccine for Elderly. Most of the 2015-16 flu vaccine protects against the three influenza viruses that will be most common this year, and is reportedly well-matched to protect you. Some seasonal flu vaccines will protect against four flu viruses. The flu shot is an inactivated vaccine contains killed virus and is approved for everyone 6 months and older, including healthy people and people with chronic medical conditions. How effective is the seasonal flu vaccine. Seasonal flu vaccine is 70 percent to 90 percent effective. This means that in a group of 10 people who receive the vaccine, it will protect 7 to 9 people from getting the flu. I got the flu last year, so will I have immunity against the flu this year. Any woman who is pregnant or nursing during flu season should get a seasonal flu vaccine. Are people who have diabetes at risk for flu-related complications. Seasonal Flu Vaccine for Children. Seasonal Flu Vaccine for the Elderly. How effective is the fl...
http://ghc.org/healthAndWellness/index.jhtml?item=/common/healthAndWellness/conditions/coldsAndFlu/flu-QandA.html
*  Healthcare Worker Influenza Vaccination Reporting
... Public Health. Communicable Disease Reporting. Healthcare-Associated Infections. Please input your facility’s rates before May 20, 2016 using the appropriate survey outlined below: Hospitals Acute Care Facilities New definition for counting healthcare personnel in an Acute Care Facility as of 2014-2015 season: Acute care hospital inpatient and outpatient counts are to be combined and submitted on a single influenza vaccination summary data form. Centers for Medicare and Medicaid Services CMS reporting requirement, IRFs and ASCs must enroll in the National Healthcare Safety Network NHSN and submit healthcare personnel influenza vaccination data using the NHSN Influenza Vaccination Module. Long-term Care Facilities LCTFs Long-term care facilities must complete the Healthcare Worker Influenza Vaccination Survey by either using the documents listed above or by completing this on-line survey . New for Outpatient Dialysis Facilities Beginning with the 2015 – 2016 influenza season, outpaient dialysis facilieits...
http://public.health.oregon.gov/DiseasesConditions/CommunicableDisease/HAI/Reporting/Pages/Influenza-Vaccination-Reporting.aspx

Flu season: Flu season is an annually recurring time period characterized by the prevalence of outbreaks of influenza (flu). The season occurs during the cold half of the year in each hemisphere.Influenza A virus subtype H1N1: Influenza A (H1N1) virus is the subtype of influenza A virus that was the most common cause of human influenza (flu) in 2009, and is associated with the 1918 outbreak known as the Spanish Flu.Influenza Research Database: The Influenza Research Database (IRD)IRD Influenza Research Database BRCSquires, R.B.Influvac: Influvac is a sub-unit vaccine produced and marketed by Abbott Laboratories. It contains inactivated purified surface fragments (sub-units) from the three different strains of the influenza virus (A/H1N1, A/H3N2, and Influenza B Virus) that are selected and distributed by the World Health Organization, on the basis of their latest recommendations.Influenza A virus subtype H5N1: Influenza A virus subtype H5N1, also known as A(H5N1) or simply H5N1, is a subtype of the influenza A virus which can cause illness in humans and many other animal species. A bird-adapted strain of H5N1, called HPAI A(H5N1) for highly pathogenic avian influenza virus of type A of subtype H5N1, is the highly pathogenic causative agent of H5N1 flu, commonly known as avian influenza ("bird flu").Global spread of H5N1 in 2006: The global spread of (highly pathogenic) H5N1 in birds is considered a significant pandemic threat.Reverse vaccinology: Reverse vaccinology is an improvement on vaccinology that employs bioinformatics, pioneered by Rino Rappuoli and first used against Serogroup B meningococcus.Pizza et al.VaccinationPandemic: A pandemic (from Greek πᾶν pan "all" and δῆμος demos "people") is an epidemic of infectious disease that has spread through human populations across a large region; for instance multiple continents, or even worldwide. A widespread endemic disease that is stable in terms of how many people are getting sick from it is not a pandemic.Polysorbate: Polysorbates are a class of emulsifiers used in some pharmaceuticals and food preparation. They are often used in cosmetics to solubilize essential oils into water-based products.TwinrixPeptide vaccine: A peptide vaccine is any peptide which serves to immunize an organism against a pathogen. Peptide vaccine are often synthetic and mimic naturally occurring proteins from pathogens.SqualaneNaked DNA: Naked DNA is histone-free DNA that is passed from cell to cell during a gene transfer process called transformation or transfection. In transformation, purified or naked DNA is taken up by the recipient cell which will give the recipient cell a new characteristic or phenotype.Global Vaccines: Global Vaccines, Inc is a mission-driven non-profit company applying state-of-the-art science and innovative business strategies to design and develop affordable vaccines for people in poor countries.Immunization during pregnancy: Immunization during pregnancy, that is the administration of a vaccine to a pregnant woman, is not a routine event as it is generally preferred to administer vaccines either prior to conception or in the postpartum period. When widespread vaccination is used, the risk for an unvaccinated pregnant patient to be exposed to a related infection is low, allowing for postponement, in general, of routine vaccinations to the postpartum period.Four Seasons Baltimore and Residences: Four Seasons Hotel Baltimore is currently a 22 story highrise hotel complex building which opened on November 14, 2011. The building's construction began back in 2007 and went through several changes.Immunologic adjuvant: In immunology, an adjuvant is a component that potentiates the immune responses to an antigen and/or modulates it towards the desired immune responses. The word “adjuvant” comes from the Latin word adiuvare, meaning to help or aid.Newmarket, Suffolk: Newmarket is a market town in the English county of Suffolk, approximately 65 miles (105 kilometres) north of London. It is generally considered the birthplace and global centre of thoroughbred horse racing and a potential World Heritage Site.Nasal administrationHIV Vaccine Trials Network: The HIV Vaccine Trials Network (HVTN) is a non-profit organization which connects physicians and scientists with activists and community educators for the purpose of conducting clinical trials seeking a safe and effective HIV vaccine. Collaboratively, research professionals and laypeople review potential vaccines for safety, immune response, and efficacy.National Outbreak Reporting System: ==The National Outbreak Reporting System (NORS)==Neuraminidase inhibitor: Neuraminidase inhibitors are a class of drugs which block the neuraminidase enzyme. They are commonly used as antiviral drugs because they block the function of viral neuraminidases of the influenza virus, by preventing its reproduction by budding from the host cell.DPT vaccineInjection site reaction: Injection site reactions are allergic reactions that result in cutaneous necrosis that may occur at sites of medication injection, typically presenting in one of two forms, (1) those associated with intravenous infusion or (2) those related to intramuscular injection.James, William; Berger, Timothy; Elston, Dirk (2005).Conjugate vaccine: A conjugate vaccine is created by covalently attaching a poor (polysaccharide) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes of the carrier to the attached antigen.Universal Immunization Programme: Universal Immunization Programme is a vaccination program launched by the Government of India in 1985. It became a part of Child Survival and Safe Motherhood Programme in 1992 and is currently one of the key areasWisconsin Alumni Research Foundation: The Wisconsin Alumni Research Foundation is the independent nonprofit technology transfer organization serving the University of Wisconsin–Madison and Morgridge Institute for Research. It provides significant research support, granting tens of millions of dollars to the university each year and contributing to the university's "margin of excellence.ImmunizationCervarixU.S.-Mexico Border Infectious Disease Surveillance Project: The U.S.OseltamivirFerret: The ferret (Mustela putorius furo) is the domesticated form of the European polecat, a mammal belonging to the same genus as the weasel, Mustela of the family Mustelidae.Harris & Yalden 2008, pp.Meningococcal vaccineBird trapping: Bird trapping techniques to capture wild birds include a wide range of techniques that have their origins in the hunting of birds for food. While hunting for food does not require birds to be caught alive, some trapping techniques capture birds without harming them and are of use in ornithology research.List of Parliamentary constituencies in Kent: The ceremonial county of Kent,AS04: AS04 (Aka. "Adjuvant System 04") is a trade name for combination of adjuvants used in various vaccine product by GlaxoSmithKline (GSK), in particular the Fendrix Hepatitis B vaccine.Plaque reduction neutralization test: The Plaque reduction neutralization test is used to quantify the titre of neutralising antibody for a virus.Virus-like particle: Virus-like particles resemble viruses, but are non-infectious because they do not contain any viral genetic material. The expression of viral structural proteins, such as Envelope or Capsid, can result in the self-assembly of virus like particles (VLPs).Pertussis vaccineDenise Faustman: Denise L. Faustman, (born 1958) is a U.Idiosyncratic drug reactionAntiviral drug: Antiviral drugs are a class of medication used specifically for treating viral infections. Like antibiotics for bacteria, specific antivirals are used for specific viruses.Cholera vaccineProportional reporting ratio: The proportional reporting ratio (PRR) is a statistic that is used to summarize the extent to which a particular adverse event is reported for individuals taking a specific drug, compared to the frequency at which the same adverse event is reported for patients taking some other drug (or who are taking any drug in a specified class of drugs). The PRR will typically be calculated using a surveillance database in which reports of adverse events from a variety of drugs are recorded.Influenza virus matrix protein 2: Matrix protein 2 of Influenza virus is a single-spanning transmembrane protein. It is expressed on the infected cell surface and incorporated into virions where it is a minor component.Kennel clubCD4 immunoadhesin: CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region.Georges Guillain: Georges Charles Guillain () (3 March 1876 - 29 June 1961) was a French neurologist born in Rouen.Typhoid vaccinePostmarketing surveillance: Postmarketing surveillance (PMS) (also post market surveillance) is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance. Since drugs are approved on the basis of clinical trials, which involve relatively small numbers of people who have been selected for this purpose - meaning that they normally do not have other medical conditions which may exist in the general population - postmarketing surveillance can further refine, or confirm or deny, the safety of a drug after it is used in the general population by large numbers of people who have a wide variety of medical conditions.Smallpox demon: or smallpox devil is a demon which was believed to be responsible for causing smallpox in medieval Japan. In those days, people tried to appease the smallpox demon by assuaging his anger, or they tried to attack the demon since they had no other effective treatment for smallpox.Kalinite: Kalinite is a mineral composed of hydrated potassium aluminium sulfate (a type of alum). It is a fibrous monoclinic alum, distinct from isometric potassium alum,American Mineralogist (1923) 8:15 named in 1868.MVA85A: MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG.Viral pneumoniaCell-mediated immunity: Cell mediated immunity is an immune response that does not involve antibodies, but rather involves the activation of phagocytes, antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. Historically, the immune system was separated into two branches: humoral immunity, for which the protective function of immunization could be found in the humor (cell-free bodily fluid or serum) and cellular immunity, for which the protective function of immunization was associated with cells.

(1/3234) Activity in saline of phthalylated or succinylated derivatives of mycobacterial water-soluble adjuvant.

A water-soluble fraction (WSA) of the cell wall can substitute for mycobacterial cells in Freund complete adjuvant. However, when WSA is administered in saline instead of in a water-in-oil emulsion, its adjuvant activity is very weak, and under certain experimental conditions it can even inhibit the humoral immune response. The data reported in the present study show that after treatment by phthalic or succinic anhydride the adjuvant activity of WSA was markedly changed, since high levels of circulating antibodies were produced when these derivatives were administered with an antigen in an aqueous medium. Moreover, the antigenic determinants of WSA were modified and acylated WSA had no tuberculin-like activity.  (+info)

(2/3234) Immunoglobulin-specific radioimmunoprecipitation assays for quantitation of nasal secretory antibodies to hemagglutinin of type A influenza viruses.

Radioimmunoprecipitation (RIP) assays were developed to selectively quantitate class-specific antibodies to purified hemagglutinins (HA) of type A influenza virus in nasal secretions. Rabbit anti-human secretory piece of immunoglobulin A (IgA) and rabbit anti-human IgG were used as second antibodies. A third antibody, goat anti-rabbit IgG, was incorporated into the system to separate immune complexes formed between iodinated HA, nasal wash test specimen, and second antibody. The utilization of this reagent avoided the need for large quantities of IgA and IgG antibody-negative carrier secretions. Nasal was specimens obtained from 14 adults immunized with an inactivated type A influenza virus vaccine were evaluated by RIP and viral neutralization assays. Significant homologous postvaccination secretory IgA and IgG antibody levels were demonstrable in 13 (93%) of individuals by RIP, whereas only 5 (36%) exhibited rises by viral neutralization tests. Moreover, the geometric mean IgA and IgG antibody levels were at least 20- and 37-fold greater than the neutralizing antibody titer. The pattern of heterologous immunoglobulin-specific antibody responses tended to be similar to those observed with the homologous HA subunit.  (+info)

(3/3234) Potential advantages of DNA immunization for influenza epidemic and pandemic planning.

Immunization with purified DNA is a powerful technique for inducing immune responses. The concept of DNA immunization involves insertion of the gene encoding the antigen of choice into a bacterial plasmid and injection of the plasmid into the host where the antigen is expressed and where it induces humoral and cellular immunity. The most effective routes and methods for DNA immunization are bombardment with particles coated with DNA ("gene gun" technique), followed by the intramuscular and intradermal routes. DNA immunization technology has the potential to induce immunity to all antigens that can be completely encoded in DNA, which therefore include all protein, but not carbohydrate, antigens. DNA immunization results in presentation of antigens to the host's immune system in a natural form, like that achieved with live-attenuated vaccines. The DNA immunization strategy has the potential to rapidly provide a new vaccine in the face of an emerging influenza pandemic.  (+info)

(4/3234) Mucosal immunity to influenza without IgA: an IgA knockout mouse model.

IgA knockout mice (IgA-/-) were generated by gene targeting and were used to determine the role of IgA in protection against mucosal infection by influenza and the value of immunization for preferential induction of secretory IgA. Aerosol challenge of naive IgA-/- mice and their wild-type IgA+/+ littermates with sublethal and lethal doses of influenza virus resulted in similar levels of pulmonary virus infection and mortality. Intranasal and i.p. immunization with influenza vaccine plus cholera toxin/cholera toxin B induced significant mucosal and serum influenza hemagglutinin-specific IgA Abs in IgA+/+ (but not IgA-/-) mice as well as IgG and IgM Abs in both IgA-/- and IgA+/+ mice; both exhibited similar levels of pulmonary and nasal virus replication and mortality following a lethal influenza virus challenge. Monoclonal anti-hemagglutinin IgG1, IgG2a, IgM, and polymeric IgA Abs were equally effective in preventing influenza virus infection in IgA-/- mice. These results indicate that IgA is not required for prevention of influenza virus infection and disease. Indeed, while mucosal immunization for selective induction of IgA against influenza may constitute a useful approach for control of influenza and other respiratory viral infections, strategies that stimulate other Igs in addition may be more desirable.  (+info)

(5/3234) Influenza vaccination among the elderly in Italy.

This article surveys the attitudes and perceptions of a random sample of the elderly population in three regions of Italy on the use and efficacy of influenza vaccine. The data were collected by direct interviews using a standard questionnaire. The results show that vaccination coverage against influenza is inadequate (26-48.6%). The major reasons for nonvaccination were lack of faith in the vaccine and disbelief that influenza is a dangerous illness. These data emphasize the need for a systematic education programme targeted at the elderly and the provision of influenza vaccination, with the increased cooperation of general practitioners.  (+info)

(6/3234) Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin.

The A/Victoria/3/75 (H3N2-subtype) hemagglutinin (HA) gene was engineered for expression in Pichia pastoris as a soluble secreted molecule. The HA cDNA lacking the C-terminal transmembrane anchor-coding sequence was fused to the Saccharomyces cerevisiae alpha-mating factor secretion signal and placed under control of the methanol-inducible P. pastoris alcohol oxidase 1 (AOX1) promoter. Growth of transformants on methanol-containing medium resulted in the secretion of recombinant non-cleaved soluble hemagglutinin (HA0s). Remarkably, the pH of the induction medium had an important effect on the expression level, the highest level being obtained at pH 8.0. The gel filtration profile and the reactivity against a panel of different HA-conformation specific monoclonal antibodies indicated that HA0s was monomeric. Analysis of the N-linked glycans revealed a typical P. pastoris type of glycosylation, consisting of glycans with 10-12 glycosyl residues. Mice immunized with purified soluble hemagglutinin (HA0s) showed complete protection against a challenge with 10 LD50 of mouse-adapted homologous virus (X47), whereas all control mice succumbed. Heterologous challenge with X31 virus [A/Aichi/2/68 (H3N2-subtype)], resulted in significantly higher survival rates in the immunized group compared with the control group. These results, together with the safety, reliability and economic potential of P. pastoris, as well as the flexibility and fast adaptation of the expression system may allow development of an effective recombinant influenza vaccine.  (+info)

(7/3234) Measuring the effects of reminders for outpatient influenza immunizations at the point of clinical opportunity.

OBJECTIVE: To evaluate the influence of computer-based reminders about influenza vaccination on the behavior of individual clinicians at each clinical opportunity. DESIGN: The authors conducted a prospective study of clinicians' influenza vaccination behavior over four years. Approximately one half of the clinicians in an internal medicine clinic used a computer-based patient record system (CPR users) that generated computer-based reminders. The other clinicians used traditional paper records (PR users). MEASUREMENTS: Each nonacute visit by a patient eligible for an influenza vaccination was considered an opportunity for intervention. Patients who had contraindications for vaccination were excluded. Compliance with the guideline was defined as documentation that a clinician ordered the vaccine, counseled the patient about the vaccine, offered the vaccine to a patient who declined it, or verified that the patient had received the vaccine elsewhere. The authors calculated the proportion of opportunities on which each clinician documented action in the CPR and PR user groups. RESULTS: The CPR and PR user groups had different baseline compliance rates (40.1 and 27.9 per cent, respectively; P<0.05). Both rates remained stable during a two-year baseline period (P = 0.34 and P = 0.47, respectively). The compliance rates in the CPR user group increased 78 per cent from baseline (P<0.001), whereas the rates for the PR user group did not change significantly (P = 0.18). CONCLUSIONS: Clinicians who used a CPR with reminders had higher rates of documentation of compliance with influenza-vaccination guidelines than did those who used a paper record. Measurements of individual clinician behavior at the point of each clinical opportunity can provide precise evaluation of interventions that are designed to improve compliance with guidelines.  (+info)

(8/3234) Detection of intracellular antigen-specific cytokines in human T cell populations.

Determination of antigen-specific cytokine responses of T lymphocytes after vaccination is made difficult by the low frequency of responder cells. In order to detect these responses, the profile of intracellular cytokines was analyzed using flow cytometry after antigenic expansion. Peripheral blood mononuclear cells were stimulated with antigens for 5 days, further expanded with interleukin (IL)-2, and then restimulated on day 10. Cytokine production was detected by intracellular staining with monoclonal antibodies after saponin-based permeabilization. Influenza expansion resulted in specific interferon-gamma (IFN-gamma) production of 6%-20%, with less IL-4 production (0%-2%). Tetanus toxoid resulted in even greater production. IL-4 and IFN-gamma were produced mainly by memory cells of the CD45RO+ phenotype. IFN-gamma production was contributed by both CD4 and CD8 populations. These methods were then applied to a clinical trial of a candidate human immunodeficiency virus type 1 vaccine. Antigen-specific increases in IFN-gamma were measured, which corresponded to antibody production, lymphoproliferation, and skin testing.  (+info)


If influenza vaccines are so effective, then why don't they work?


If influenza vaccines are so effective, then why don't they work to protect people that have been getting their flu shots all these years?
----------

Who says they haven't worked to protect people that have been getting the shots all these years? Whoever told you that is wrong.

The Flu shot does work. It is not a 100% sort of thing, but it works quite well. Keep in mind that there are many many different strains of the flu and the people who make the shot have to take a guess ahead of time as to which strain to make a vaccine for that year. But you could get a shot for strain xyz, and if you come in contact with another strain then your vaccine won't do you much good.


What would happen to someone who has had the Influenza vaccine (flu jab) when Influenza infects him/her?


What would happen to someone who has had the Influenza vaccine (flu jab) when Influenza infects him/her. Oppose to someone who didn't have any vaccine against the virus. 

I need a scientific answer oppose to a NHS answer. 

I know that white blood cells would have already produced antibodies for Influenza, but would that be enough to be totally virus free? 

Thanks!
----------

There bodies would be full of antibodies for whatever strain of flu they got vaccinated by.  

*IF* the strain they were infected by happened to be a strain they were vaccinated against, the antibodies would instantly start attaching to the virus. The antibodies would function as targets and the white blood cells would attack the viruses that had been tagged by the antibodies.  This means your adaptive immune system has a "head start".

If you have a strong enough immune system, your body might wipe out the virus before you notice you are sick.  If your immune system is weak, you might get sick anyway.)

If you weren't vaccinated, your immune system might not notice and start fighting it until you start feeling sick, and the adaptive immune system can take weeks to get involved.  (Usually the innate immune system handles the problem before then, but you feel sick when your innate immune system activates.


For how long will the influenza vaccine stay in your system?


Hello Everyone,
I just got an influenza vaccine shot, after I had it; someone told me that I shouldn’t have it because is not good for you.  Will this vaccine stay in my body for the rest of my live, or would it be out of my system in a few months, years?
Thanks everyone,
----------

The vaccine is safe. You have nothing to worry about. Nothing in the vaccine is in harmful amounts. Most ingredients are eliminated in very short space of time. Ignore stupid people.

You're fine.


HIB vaccine not lowercased on immunization record, is it the same as Hib?


I'm submitting my immunizations for college and it is asking for the Hib influenza vaccine. My mom doesn't think she's gotten me vaccinated for influenza before, and I'm not sure if these two vaccinations (HIB and Hib) are the same. Can someone enlighten me on this?
----------

Hib is not an influenza vaccine, though it sounds like it would be (it is short for Haemophilus influenzae type b, but has nothing to do with influenza).  See which one they want- Hib or influenza.  If you are healthy and over 5 years old, there is no indication for the Hib vaccine at this point and I doubt that the college would be asking for it, but if you got it as a child you can go ahead and put the dates down.  They may want you to have a current influenza vaccine.


Could my sore throat be caused by this vaccine?


I got the Influenza vaccine Wednesday, and the RN said that I might get a sore throat. I actually got the nasal spray. BUT, there have been a lot of cases of Viral Pharyngitis at school, and my symptoms are much like those of Viral Pharyngitis, and I have swollen lymph nodes. Could it be the vaccine or Viral Pharyngitis?
I forgot to mention that I have a sore throat, it's moderate.
----------

If you got the FluMist, your symptoms may be related to the vaccine.  But since so many people at your school are ill, viral pharyngitis is also a possibility.


how is the swine flu vaccine different from the seasonal vaccine?


in biology a few years ago we talked about how scientists look at trends and predict what the seasonal flu is going to be, and then make it into a vaccine. Is that all they did with the swine flu? are they doing what they always do and just putting in the h1n1 strain? that's what i originally thought but now we're all hearing how the vaccine is rushed because they made it so quickly and the vaccine is worse than the actually flu and such. is it really necessary to debate whether to get the vaccine or not? or is it the same kind of influenza vaccine we've been using for years?
----------

It is exactly like seasonal flu vaccine, only it's targeted against H1N1.

From the CDC website:  "The same manufacturers who produce seasonal flu vaccines are producing 2009 H1N1 vaccines for use in the United States and the vaccines are being made in the same way that the seasonal vaccines are made."


Is there anyway to prevent a child from becoming ill after being around someone sick?


I am curious if there are any homeopathic remedies to give a child to prevent them from becoming ill right after being around another sick child? Hand washing & influenza vaccine were put into practice, but I am wondering if there is anything that can be given to minimize the chance of getting ill from being around someone sick.
Thanks!
----------

Try hand sanitizer, and don't be around other sick kids. Also, not touching your face, eyes or mouth; avioding very close contact with those who are sick; clean and disinfect surfaces often; and Eat a balanced diet and get proper rest


Wondering if the regular flu shot will help minimize swine flu symptoms?


As there are many questions arising about the swine flu, the regular flu and all of the vaccinations, a lot of us have been curious about something.  Has anyone out there who HAD the swine flu or currently has the swine flu received a regular influenza vaccine prior to getting sick with the H1N1 virus?  Thank you for your input.  It is greatly appreciated.
----------

What's more interesting is that what you're asking can't be determined from what information you're looking for. What do I mean:

You want input from someone who has gotten the seasonal flu shot and has also tested positive for infection with the H1N1 flu strain. What do you expect someone to say from this subgroup that would indicate the seasonal flu shot provides protection from H1N1?

Do you not realize that to confirm a positive benefit, someone would have to say, "Yes, I got the seasonal flu shot and tested positive for H1N1 but never got symptomatic" in order to say there is some kind of protection from H1N1 when you get the seasonal flu shot. Highly unlikely anyone would even be tested if not symptomatic. The only answers you'll get are from people who got only the seasonal flu shot and then got symptomatic and tested positive for the H1N1, which would then tell you the seasonal flu shot provides no protection from H1N1.